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The DNA mismatch repair (MMR) pathway, a crucial post-replicative repair pathway, is essential
to the maintenance of genomic stability. Consequentially, loss of MMR increases mutation
frequency, promoting tumorigenesis. However, if and how MMR activity coordinates with cellular
replication forks is unclear. Particularly, at forks encountering lesions that cannot be faithfully
replicated, like O6-methylguanine (MeG) lesions created by DNA alkylating agents, MMRdirected processing of resultant mismatches could disrupt fork progression. Yet the events
following lesion recognition remain elusive. In transformed cells MMR-dependent

Me

G/T

recognition in the first S phase elicits a permanent G2 arrest in the subsequent cell cycle. Yet,
in human pluripotent stem cells (hPSCs), it activates an immediate and robust MMR-dependent
apoptotic response. In this study, we ascertained how

Me

G/T lesion recognition affects the first

S phase in human embryonic stem cells (hESCs) and transformed HeLa cells. MMR-proficient
HeLa cells exposed to alkylation damage activated ataxia telangiectasia and Rad3-related
(ATR)-Checkpoint Kinase 1 (Chk1) signaling, slowing progression through the first S phase. Yet,
DNA replication is completed, and cells progress into the next cell cycle. Conversely, inhibition
of ATR-Chk1 signaling accelerates S phase progression, damage accumulation and sensitivity
to DNA alkylating agents. In addition, as MMR-proficient human embryonic stem cells exposed
to alkylation damage fail to activate ATR-Chk1 signaling, MMR activity severely compromises
DNA replication leading to accumulation of toxic double strand breaks and rapid apoptotic
induction. We propose that MMR-directed futile repair cycles disrupt fork progression implicating
the MMR-directed repair of alkylation damage as a replication stress inducer.

Dipika Gupta, University of Connecticut, 2018

Thereafter, ATR-Chk1 mediated intra-S phase checkpoint activation mitigates replication stress
and facilitates completion of replication. Absence of this signaling, however, accelerates
damage accumulation and sensitivity to alkylating agents. This work changes how we view this
post-replicative repair pathway, suggesting a coordination between MMR activity and the DNA
replication machinery. In addition, these results reveal that different cell types may have different
levels of sensitivity to MMR processing of lesions. Taken together, this work provides the
foundation for understanding how MMR is executed at cellular replication forks and has crucial
implications for the mechanism of MMR, early tumorigenesis, cancer prevention and
chemotherapeutics.
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Desiderata
Go placidly amid the noise and haste,
and remember what peace there may be in silence.
As far as possible without surrender be on good terms with all persons.
Speak your truth quietly and clearly; and listen to others, even the dull and the ignorant;
they too have their story.
Avoid loud and aggressive persons, they are vexations to the spirit.
If you compare yourself with others, you may become vain and bitter;
for always there will be greater and lesser persons than yourself.
Enjoy your achievements as well as your plans.
Keep interested in your own career, however humble;
it is a real possession in the changing fortunes of time.
Exercise caution in your business affairs; for the world is full of trickery.
But let this not blind you to what virtue there is;
many persons strive for high ideals; and everywhere life is full of heroism.
Be yourself.
Especially, do not feign affection.
Neither be cynical about love; for in the face of all aridity and disenchantment
it is as perennial as the grass.
Take kindly the counsel of the years,
gracefully surrendering the things of youth.
Nurture strength of spirit to shield you in sudden misfortune.
But do not distress yourself with dark imaginings.
Many fears are born of fatigue and loneliness.
Beyond a wholesome discipline, be gentle with yourself.
You are a child of the universe, no less than the trees and the stars;
you have a right to be here.
And whether or not it is clear to you, no doubt the universe is unfolding as it should.
Therefore be at peace with God, whatever you conceive Him to be,
and whatever your labors and aspirations,
in the noisy confusion of life keep peace with your soul.
With all its sham, drudgery, and broken dreams, it is still a beautiful world.
Be cheerful.
Strive to be happy.
-
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CHAPTER 1

INTRODUCTION

I. LYNCH SYNDROME:

Lynch syndrome (LS) accounts for 2-7% of all colon cancer cases and is the most common
form of hereditary colon cancer. Although initially described as a colon cancer predisposition
syndrome, this syndrome confers an 80-90% risk of developing a broad spectrum of cancers
including that of the endometrium, small bowel and pancreas (Heinen 2014, Lynch, Snyder et al.
2015). This autosomal dominant disease is caused by the inheritance of mutations in one of four
DNA mismatch repair (MMR) genes. Initially heterozygous for the mutant MMR gene, a
spontaneous mutation or loss of heterozygosity event at the wild type allele confers complete loss
of MMR function. MMR plays a crucial role in the maintenance of genomic stability. In repairing
DNA mismatches and insertion/deletion loops (IDLs) that result during DNA replication, MMR is
crucial to increasing DNA replication fidelity. Conversely, loss of MMR confers polymerase
slippage events refractory to repair causing expansion or contraction of microsatellite repeat
regions (Kunkel and Erie 2005). Consequentially, the identification of microsatellite instability
(MSI) as a molecular phenotype characteristic to LS associated tumors in the early 1990’s
implicated affected MMR function as the genetic cause of LS (Aaltonen, Peltomaki et al. 1993,
Fishel, Lescoe et al. 1993, Bronner, Baker et al. 1994). Yet, the exact mechanism by which MMR
loss contributes to tumorigenesis is unclear.
Although, MMR fits the classical definition of a tumor suppressor, wherein both wild type
copies must be lost for tumorigenesis, the mechanism by which MMR loss contributes to
tumorigenesis is likely more indirect. Upon loss of MMR, DNA polymerase mistakes are made
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permanent in the genome in the subsequent S phase. Mutation frequency increases several
hundred-fold conferring a mutator phenotype (Kunkel and Erie 2005). The subsequent
accumulation of mutations in tumor suppressor genes and oncogenes is predicted to be a driver
of tumorigenesis. In addition, frameshift mutations could result from extension and contraction of
nucleotide repeats within the coding regions of genes due to polymerase slippage causing loss
of protein function. Particularly, in LS-related cancers these events have been identified in various
tumor suppressor genes like adenomatous polyposis coli, proapoptotic BCL2-associated X
protein (BAX) and transforming growth factor-β type II receptor (TGFBR2) (Duval and Hamelin
2002, Heinen 2014, Lynch, Snyder et al. 2015). In addition, MMR protects genomic integrity by
inducing apoptosis in response to exposure to DNA damaging agents like N-nitroso compounds.
Although recognized as dietary carcinogens, N-nitroso compounds also arise as metabolic
byproducts of colonic bacterial populations (Povey, Hall et al. 2000). Cells resident to these toxic
environments likely experience an increased selection pressure to lose MMR function to bypass
the MMR-dependent cytotoxicity of these agents, promoting survival (Heinen, Schmutte et al.
2002). Additionally, the mutagenic nature of these agents could further contribute to
tumorigenesis by compounding the accumulation of somatic mutations. Together, MMR loss
could confer a selective growth advantage through the accumulation of growth promoting somatic
mutations and/or increased resistance to DNA damaging agents.
LS-associated colorectal cancers display certain key clinicopathological features. Cancers
develop at early age and typically develop in the proximal colon. In addition, cancer progression
from polyp formation to carcinoma can take as little as 2-3 years compared to the 6–10 years
reported in sporadic cancer patients. The rapid accumulation of somatic mutations upon MMR
loss likely contributes to this accelerated tumorigenesis phenotype. The poor differentiation of
these tumors is characterized by mucinous features, signet ring cells and medullary cell types.
These cancers do not display polyploidy but are positive for infiltrating T- lymphocytes and Crohn-
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Table 1-1. Bethesda Guidelines that warrant further testing for LS

1. Colorectal cancer diagnosed in a patient who is ˂50 years of age
2. Presence of synchronous or metachronous colorectal cancer or other LS-associated
cancer, regardless of age
3. Colorectal cancer with MSI-high histology in a patient who is ˂60 years of age
4. Colorectal cancer or LS-associated cancer diagnosed in ≥1 first-degree relatives who
is ˂50 years of age
5. Colorectal cancer or LS-associated cancer diagnosed in ≥2 first- or second-degree
relatives regardless of age

Adapted from (Umar, Boland et al. 2004, Heinen 2014, Lynch, Snyder et al. 2015)
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like lymphocytic reaction. These histological features are characteristic of tumors with high MSI.
The Revised Bethesda guidelines, is the latest in a series of international guidelines put forth to
identify individuals that must undergo further testing for LS (Table 1-1). However, more recently
MSI testing and loss of MMR protein expression by immunohistochemistry are routinely used to
screen all colon cancer patients, regardless of age and family history, to identify potential LS
patients (Heinen 2014, Lynch, Snyder et al. 2015). As of 2015, nearly 74% of LS cases are
associated with the inheritance of mutations in MMR genes MSH2 and MLH1 while only 18% and
8% carry mutations in MMR genes, MSH6 and PMS2, respectively (Peltomaki 2016).

II. DNA MISMATCH REPAIR

i. MMR IN E.COLI
As mentioned previously, MMR plays an essential role in increasing replication fidelity and
the maintenance of genomic stability. Unsurprisingly, MMR is highly conserved through evolution
and has been studied in numerous model systems. The mechanistic details of MMR are most
completely understood in E. coli. In vitro studies utilizing engineered hemimethylated mismatch
containing DNA substrates have identified the minimal factors essential to repair. These include
MutS, MutL, MutH, DNA helicase II (UvrD), exonuclease I, single-strand binding (SSB) protein,
DNA ligase, and DNA polymerase holoenzyme III (Fig. 1-1) (Lahue, Au et al. 1989). In vitro,
mismatches on engineered hemimethylated DNA substrates are recognized by the MutS
homodimers which interacts with the mismatch asymmetrically (Lamers, Perrakis et al. 2000).
The phenylalanine residue of the Phe-X-Glu motif within one of the MutS subunits inserts into and
stacks with the mispaired bases. This is further stabilized through hydrogen bonding interactions
with the glutamine residue (Lamers, Perrakis et al. 2000, Kunkel and Erie 2005). Mismatch
binding triggers an ADP to ATP exchange within MutS and recruits MutL to form a ternary complex
(Galio, Bouquet et al. 1999). A second ADP to ATP exchange within MutL promotes the interaction
4

Fig 1-1. Model of mismatch recognition by MMR proteins in E. coli
Upon recognizing DNA mismatches, bacterial MutS homodimer recruits MutL to form a ternary
complex. Together, they activate MutH endonuclease activity to recognize transiently hemimethylated GATC sites behind replication forks and nick the unmethylated strand. This creates
an entry site for UvrD helicase and exonucleases that proceed to excise the erroneous nascent
strand. ssDNA gaps are protected by binding of single stranded DNA binding protein SSB. DNA
polymerase and ligase proceed to complete repair by filling and sealing the gaps. (Reproduced
with permission from (Jiricny 2006))
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and activation of the endonuclease activity of MutH (Ban and Yang 1998, Junop, Obmolova et al.
2001). Once activated, MutH cleaves the GATC sequence specifically on the nascent strand. This
strand discrimination signal is provided by the transient unmethylated state of GATC sequence
on the nascent strand due to the lagging of the deoxyadenine methylase enzyme behind the
replication by approximately 2 min (Langle-Rouault, Maenhaut-Michel et al. 1987, Welsh, Lu et
al. 1987, Jiricny 2013). UvrD helicase loaded at sites of incision then proceed to unwind nascent
strand DNA past the mismatch. SSB bind to and protect ssDNA template stretches as excision of
the erroneous strand is accomplished by ExoI or ExoX (5’-3’exonucleases), and ExoVII or RecJ
(3’-5’ exonucleases). DNA polymerase proceeds to fill the gap in the daughter strand. Repair is
completed by the sealing of the remaining nick by DNA ligase (Li 2008).

ii. EUKARYOTIC MMR
An understanding of prokaryotic MMR has been crucial in informing the identification of
eukaryotic MMR proteins. Although eukaryotic MMR has been reconstituted in vitro, differences
in components and functions of MMR’s eukaryotic counterparts have yet to gain us a complete
understanding of this process (Table 1-2). By assessing correction of mismatches on engineered
heteroduplex substrates, minimal factors essential for repair have been identified. For eukaryotic
MMR to proceed further in vitro, engineered heteroduplex substrates must contain a preexisting
nick 3’ or 5’ to the mismatch (Fig. 1-2) (Holmes, Clark et al. 1990, Thomas, Roberts et al. 1991).
The context of the nick in relation to the mismatch has provided key insights into the mechanism
of MMR. Firstly, the nick provides a crucial strand discrimination signal, directing repair specifically
to the nick containing strand. This is crucial as eukaryotic MMR does not depend on transient
hemimethylation at d(GATC) sequences on the newly-synthesized DNA strand as a strand
discrimination signal nor have any eukaryotic homologues of bacterial MutH been identified to
date. In vivo, gaps generated during discontinuous synthesis of Okazaki fragments could serve
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Table 1-2. MMR component functions in E. coli and humans

E. coli

Eukaryotes

Function

MutS

MSH2-MSH6

Mismatch recognition

MSH2-MSH3

Insertion/deletion loop (IDL) recognition

MutL

MLH1-PMS2

Molecular
matchmaker;
strand
endonuclease, termination of excision

MutH

-

Strand specific endonuclease; nicks newly
synthesized DNA at hemimethylated GATC sites

UvrD

-

DNA helicase

ExoVII, RecJ

-

3’-5’ Exonuclease for mismatch excision

ExoI, ExoX

ExoI

5’-3’ Exonuclease for mismatch excision

Pol III holoenzyme

DNA pol δ/ε.

Repair synthesis

β clamp

PCNA

DNA polymerase processivity factor; molecular
matchmaker between MMR and replication fork;
activates MLH1-PMS2 endonuclease activity for
3’ nick directed MMR

γ complex

RFC

Loads β clamp and PCNA respectively; activates
MLH1-PMS2 endonuclease activity for 3’ nick
directed MMR

SSB

RPA

Single-stranded DNA binding protein

Adapted from (Jiricny 2013)
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specific

as discrimination signals on the lagging strand. Until recently however, the sources of such strand
discontinuities on the leading strand remained enigmatic. Interestingly, it was observed that DNA
polymerase ε incorporates ribonucleotides into the leading strand. Gaps generated upon
recognition and removal of these erroneous ribonucleotides lesions by RNase H2 serve as a
source of strand discontinuities and a discrimination signal for MMR on the leading strand
(Ghodgaonkar, Lazzaro et al. 2013, Lujan, Williams et al. 2013). Additionally, it is unknown if this
is the only possible source of strand discontinuities on the leading strand, particularly given the 3’
terminus on the leading strand at the replication fork.
Minimal factors essential to MMR in vitro differ based on the orientation of the nick relative
to the mismatch. 5'-nick directed MMR requires the human homologue of MutS, exonuclease 1
(EXO1), replication protein A (RPA), replication factor C (RFC), proliferating cell nuclear antigen
(PCNA) and DNA polymerase δ/ε (Fig. 1-2) (Constantin, Dzantiev et al. 2005, Zhang, Yuan et al.
2005, Bowen and Kolodner 2017). DNA mismatches are first recognized by the eukaryotic
homologue of MutS. Humans express three MutS homologues involved in MMR, MSH2, MSH6
and MSH3. Both MSH6 and MSH3 form partially redundant heterodimers with their obligate
partner, MSH2. MSH2-MSH6 complex recognizes single base pair mismatches and 1-2 base
insertion/deletion loops (IDLs) while MSH2-MSH3 recognizes IDLSs (Li 2008, Jiricny 2013). The
functional asymmetry of the bacterial MutS homodimer is conserved within the MSH2-MSH6 and
MSH2-MSH3 heterodimers. The highly conserved Phe-X-Glu motif within MSH6 interacts with
and contacts the mismatch in a mechanism similar to that described for bacterial MutS mismatch
recognition (Warren, Pohlhaus et al. 2007). This triggers an ADP to ATP exchange within the
ABC-ATPase domains of both MSH2 and MSH6. Nucleotide binding, but not ATP hydrolysis,
drives a conformational change within MSH2-MSH6 into a sliding clamp capable of diffusing along
DNA (Gradia, Acharya et al. 1997, Gradia, Subramanian et al. 1999, Heinen, Cyr et al. 2011).
This frees the DNA mismatch to initiate loading of additional MSH2-MSH6 clamps. DNA bound
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MSH2-MSH6 can load the 5′ to 3′ exonuclease EXO1 onto the 5’-strand discontinuity leading to
the excision of the nick containing strand. Although not essential to 5’-directed MMR, eukaryotic
homologue of MutL, the MLH1-PMS2 heterodimer, is required to regulate excision by Exo1
(Genschel, Bazemore et al. 2002). By interacting with MSH2-MSH6 complex in an ATPdependent manner, MLH1-PMS2 is recruited to mismatch containing DNA substrates and
regulates Exo1 such that strand excision terminates approximately 150 nucleotides beyond the
mismatch (Genschel, Bazemore et al. 2002, Zhang, Yuan et al. 2005). Correspondingly, Exo1
generates large excision tracts in the absence of MLH1-PMS2. The corresponding ssDNA
stretches are coated and protected by ssDNA binding protein, RPA. The clamp loader, RFC, loads
the DNA polymerase processivity factor PCNA onto 3’ ends of resulting gaps. Gaps are then filled
and sealed by DNA polymerase δ/ε and DNA ligase respectively (Longley, Pierce et al. 1997, Gu,
Hong et al. 1998, Lin, Shivji et al. 1998).
Understanding strand excision reactions for 3'-nick directed MMR posed a significant
challenge as the only identified exonuclease to participate in eukaryotic MMR is the obligate 5’-3’
Exo 1. However, as MMR proceeded on 3'-nicked substrates, Exo 1 was suggested to have a
cryptic 3’-5” exonuclease activity. Subsequently, the PMS2 subunit of the MLH1-PMS2
heterodimer was identified to possess a latent endonuclease activity that is essential for 3'-nick
directed MMR (Kadyrov, Dzantiev et al. 2006, Kadyrov, Holmes et al. 2007). After MSH2-MSH6
dependent recruitment to heteroduplex DNA, both PCNA and RFC are required to activate the
endonuclease activity of PMS2. Furthermore, by interacting with only one of the asymmetric ring
faces of PCNA, loading of PCNA by RFC at 3’-ends ensures that PMS2 is oriented such that is
only capable of incising the daughter strand (Pluciennik, Dzantiev et al. 2010). Consequentially,
changing the orientation of PCNA loading on mismatch containing substrates dictates strand
specificity for PMS2 nicking. MLH1-PMS2 endonuclease activity can generate nicks 5’ of the
mismatch. Exo1 can proceed with 5’-3’ excision of the nicked strand followed by strand
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Fig 1-2. An extrapolated prediction of the MMR mechanism at replication forks based on
data from MMR directed repair of 5’ and 3'-nicked heteroduplex DNA substrates in-vitro.
DNA mismatches can escape replicative polymerase proofreading on both the leading and
lagging strands. These are recognized by eukaryotic MMR heterodimer, MSH2-MSH6, which
recruit a second MMR heterodimer, MLH1-PMS2. Correction of mismatches on the lagging strand
would likely parallel those observed in in vitro 5’-nick MMR reactions. Strand discontinuities
created during Okazaki fragment synthesis could serve as entry sites for Exo1 that would proceed
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to excise the daughter strand in the 5’-3’ direction. DNA polymerase synthesizing the preceding
Okazaki fragment can continue to rereplicate the excised DNA fragment leading to mismatch
correction. Alternatively, in an Exo1 independent mechanism the latent endonuclease activity of
PMS2 is activated to generate a nick 3’ of the mismatch. DNA polymerase synthesizing the
preceding Okazaki fragment can simultaneously rereplicate and displace the error containing
daughter strand leading to mismatch correction. Alternatively, nicks generated by PMS2 might
regulate Exo1 directed strand excision. Correction of mismatches on the lagging strand would
likely parallel those observed in in vitro 3’-nick MMR reactions. Herein, the latent endonuclease
activity of PMS2 would be essential for generating nicks on the daughter strand 5’ of the
mismatch. This could serve as entry sites for Exo1 that can excise the daughter strand in the 5’3’ direction and DNA polymerase directed strand resynthesis. Alternatively in an Exo1
independent mechanism nicks generated could initiate DNA polymerase strand resynthesis and
simultaneous displacement of the error containing daughter strand leading to mismatch correction
(Reproduced with permission from (Kazak, Reyes et al. 2012)).
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resynthesis and ligation by DNA polymerase δ/ε and DNA ligase respectively. Alternatively, MMR
can proceed via a less efficient Exo1 independent pathway wherein 5’-3’ DNA polymerase δ
directed extension from nicks drives strand displacement and mismatch correction (Fig. 1-2)
(Kadyrov, Genschel et al. 2009).

III. DAMAGE SIGNALING:

In addition to its role in removing DNA replication errors, the MMR system is also essential
for eliciting a cytotoxic response to certain DNA damaging agents, particularly SN1 DNA alkylating
agents (Duckett, Drummond et al. 1996, Li, Pearlman et al. 2016). This role of MMR was first
identified in E. coli, wherein MMR loss conferred increased resistance to the SN1 DNA alkylating
agent, N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) (Karran and Marinus 1982). By the mid
1990’s, loss of MMR in various eukaryotic systems was shown to result in 100-fold decease in
sensitivity to MNNG (Goldmacher, Cuzick et al. 1986, Karran 2001). These results suggested that
MMR deficient tumors might be immune to chemotherapeutic DNA methylating agents used in
the clinic like temozolomide (Drablos, Feyzi et al. 2004, Kaina, Christmann et al. 2007).
SN1 DNA alkylating agents create a spectrum of DNA damage that is counteracted and
repaired by different repair pathways, like base excision repair, nucleotide excision repair,
homologous recombination (HR) and non-homologous end joining (NHEJ) (Fu, Calvo et al.
2012). However, MMR-dependent cytotoxicity is elicited in response to mutagenic

Me

G adducts,

that account for just 7% of lesions formed (Beranek 1990, Wyatt and Pittman 2006). An
endogenous repair enzyme methylguanine methyl transferase (MGMT) is the first line of defense
against these cytotoxic

Me

G lesions. In a suicide reaction, MGMT directs transfer of the methyl

group onto itself which triggers MGMT inactivation and proteasomal degradation (Margison and
Santibanez-Koref 2002, Gerson 2004, Kaina, Christmann et al. 2007). But

Me

G lesions that

escape this repair are preferentially mispaired with thymidine during DNA replication (Murray
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1987). These MeG/T mismatches are a substrate for MMR directed repair and/or signaling, which
culminates in the elimination of these damaged cells (Fig. 1-3) (Duckett, Drummond et al. 1996,
Kaina, Ziouta et al. 1997). Conversely, in the absence of active or functional MMR,

Me

G/T

mismatches go unrecognized, resulting in the acquisition of G to A transition mutations in the
subsequent cell cycle (Altshuler, Hodes et al. 1996). Loss of MMR therefore confers a
"methylation tolerant" phenotype wherein the once cytotoxic

Me

G become mutagenic and

carcinogenic (Karran 2001).
The MMR-dependent cytotoxic response is elicited specifically in response to low dose
exposure to alkylation damage (Stojic, Mojas et al. 2004). A defining feature of this response
includes the induction of a G2 arrest, but only after cells have traversed through two S-phases
(Stojic, Mojas et al. 2004, Mojas, Lopes et al. 2007, Mastrocola and Heinen 2010). Although MMR
proteins recognize engineered

Me

G/T mismatches on DNA substrates in vitro, the molecular

events following this recognition are unclear (Duckett, Drummond et al. 1996). All encompassing,
two models have been proposed. The first model suggests that MMR directs excision on the newly
synthesized daughter strand (Fig. 1-3). Hence, during resynthesis persistence of MeG on template
DNA drives the recreation of the

Me

G/T mismatch (Kaina, Ziouta et al. 1997, Stojic, Mojas et al.

2004, Mojas, Lopes et al. 2007). In this manner, MMR-directed MeG/T recognition initiates iterative
cycles of futile repair. In support of this futile cycle model, introduction of an irreparable MeG base
on the template DNA drives repeated MMR directed strand excision and gap filling across from
Me

G lesions (York and Modrich 2006). Correspondingly, loss of murine Exo1 or expression of an

endonuclease dead PMS2 mutant in PMS2-/- cells confers resistance to alkylation damage,
emphasizing the role of tract excision and processing in this MMR-directed DNA damage
response (Erdeniz, Nguyen et al. 2007, Klapacz, Meira et al. 2009). Also, inability to faithfully
repair and replicate these regions yields ssDNA gaps in both yeast and human cancer cells
(Mojas, Lopes et al. 2007). Through mechanisms that are not well understood the ssDNA gaps
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are tolerated, and cells continue progression into the next cell cycle. Forks encountering gapped
template DNA collapse, leading to accumulation of double strand breaks (DSBs) (Stojic, Mojas et
al. 2004, Mojas, Lopes et al. 2007). The collapsed forks and DSBs can be rescued by HR as
evidenced by an increase in sister chromatid exchange (SCE) (Mojas, Lopes et al. 2007).
Correspondingly, loss of HR further sensitizes MMR-proficient yeast and human cells to the
cytotoxicity of MNNG, which is alleviated upon MMR loss. Inability to resolve all DSBs however
triggers permanent G2 arrest through the activation of DNA damage sensing kinases and
checkpoint proteins like Ataxia Telangiectasia and Rad3-related (ATR), Ataxia Telangiectasia
mutated (ATM), checkpoint kinase 1 (Chk1) and checkpoint kinase 2 (Chk2) (Stojic, Mojas et al.
2004, Mojas, Lopes et al. 2007, Mastrocola and Heinen 2010). Therefore, in this model secondary
damage accumulation, like ssDNA gaps and DSBs, resulting from MMR-directed futile repair is
responsible for cytotoxicity of

Me

G lesions.

An alternative model suggests that MMR proteins recognizing

Me

G/T mismatches are

capable of directly activating DNA damage responses (Fig. 1-3). In this direct signaling model,
MMR proteins along with other factors act as a platform for the recruitment and activation of DNA
damage sensing kinases and checkpoint points (Yoshioka, Yoshioka et al. 2006, Li, Pearlman et
al. 2016). In support of this, MSH2 was found to interact with ATR directly in vitro (Wang and Qin
2003). ATR, Chk1 and Chk2 coimmunoprecipitate with MSH2-MSH6 complex in response to
alkylation damage (Brown, Rathi et al. 2003, Adamson, Beardsley et al. 2005, Liu, Fang et al.
2010). Similarly, MLH1-PMS2 complex interacts with ATR-activator, TOPBP1 (Topoisomerase IIbinding protein 1) and ATM (Brown, Rathi et al. 2003, Liu, Fang et al. 2010). Interestingly, other
canonical factors important to ATR-Chk1 activation did not enrich on damaged chromatin or
interact with MMR proteins (Liu, Fang et al. 2010) . Additionally, in vitro MMR proteins activate
ATR-Chk1 kinases in response to MeG/T and not G/T mismatches containing DNA substrates
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Fig 1-3. Processing and repair of cytotoxic MeG lesions created upon exposure to SN1 DNA
alkylating agents.
Alkylation of guanine residues by SN1 DNA alkylating agents creates a mutagenic

Me

G lesion

within DNA. These lesions can be directly repaired by O6-methylguanine-DNA methyltransferase
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(MGMT). But MeG lesions that escape this repair are preferentially mispaired with thymidine during
DNA replication. IN the MMR-directed futile cycle model,

Me

G/T mismatch recognition by

eukaryotic MMR homologue MutSα (MSH2-MSH6) initiates excision and resynthesis of error
containing daughter strand. However, persistence of

Me

G on the template DNA leads to MMR-

directed futile cycles of repair. Inability to replicate across

Me

G lesions causes ssDNA gap

accumulation without affecting cell cycle progressing. In the subsequent S phase however,
replication forks collapse at these gapped substrates causing DSB accumulation. This activates
ATR-Chk1 and ATM-Chk2 DNA damage signaling causing a G2 arrest. Although HR repair
attempts repair of these DSBs at the expense of accumulating sister chromatid exchanges (SCE)
and chromosomal aberrations, the overwhelming burden of cytotoxic DSBs leads to cell death.
Therefore, in this model secondary damage accumulation, like ssDNA gaps and DSBs, resulting
from MMR-directed futile repair is responsible for cytotoxicity of

Me

G lesions. Alternatively, the

MMR directed recognition of MeG lesions has been suggested to initiate a direct signaling module
wherein DNA damage sensing kinases and their co-activators, create a platform at

Me

G/T

mismatches for the activation of ATR-Chk1 signaling and ATM-Chk2 signaling that can lead to
activation of a G2 arrest and eventually cell death. (Adapted with permission from (Fu, Calvo et
al. 2012))
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(Yoshioka, Yoshioka et al. 2006). But most strikingly, mouse embryonic fibroblasts expressing
missense mutants of Msh2G674A and Msh6T1217D that abrogated mismatch correction still
retained sensitivity to MNNG (Lin, Wang et al. 2004, Yang, Scherer et al. 2004). Together, these
finding suggested that by directly interacting with DNA damage sensing kinases and their coactivators, MMR proteins act as a platform at

Me

G/T mismatches for the activation of ATR-Chk1

and ATM-Chk2 signaling. However, this model fails to explain why MMR proteins that respond to
Me

G/T in the first S-phase, elicit a cell cycle arrest only in the second cell cycle after damage

exposure.

IV. HUMAN PLURIPOTENT STEM CELLS

During development, embryonic stem cells (ESCs) divide rapidly and differentiate into all
cell lineages of the organism. Thus, acquisition and propagation of genomic aberrations in hESCs
could have deleterious consequences for development and tissue homeostasis, promoting
disease and even death. Hence the need for maintenance of genomic stability is likely heightened
in these cells (Rocha, Lerner et al. 2013). Furthermore, the ability to fine tune culture conditions
to direct differentiation of human pluripotent stem cells (hPSCs) such as hESCs and induced
pluripotent stem cells into specific cell types creates tremendous potential for their use in
regenerative medicine, disease modeling, drug screening and testing. Yet a lack of a thorough
understanding of how they deal with genotoxic stresses limits their potential in regenerative
medicine.
Initial studies have demonstrated certain recurring themes by which hPSCs deal with DNA
damage. They have an increased propensity to undergo apoptosis when exposed to various
genotoxic stresses (Adams, Golding et al. 2010, Barta, Vinarsky et al. 2010, Momcilovic,
Knobloch et al. 2010, Wilson, Sun et al. 2010, Fan, Robert et al. 2011, Desmarais, Hoffmann et
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al. 2012, Luo, Gopalakrishna-Pillai et al. 2012, Sokolov and Neumann 2012, Insinga, Cicalese et
al. 2013, Liu, Guan et al. 2013, Rocha, Lerner et al. 2013, Suvorova, Kozhukharova et al. 2013).
The tumor suppressor p53 is a crucial effector of the apoptotic response in hPSC (Qin, Yu et al.
2007, Dumitru, Gama et al. 2012, Liu, Guan et al. 2013). Exposure to genotoxic stress causes
stabilization and activation of a p53 dependent apoptotic response. In somatic cells, stressinduced p53 engage in transcription dependent and independent modes of apoptotic induction
(Villunger, Michalak et al. 2003, Green and Kroemer 2009). In hPSCs however, p53’s role as a
trans-activator of pro-apoptotic genes is dispensable for apoptotic induction. Reduction in p53
expression but not inhibition of p53-nuclear translocation attenuates apoptotic induction in
damaged hPSCs (Grandela, Pera et al. 2007, Qin, Yu et al. 2007). Conversely, translocation of
p53 to the mitochondria is essential for activating the apoptotic response (Grandela, Pera et al.
2007, Qin, Yu et al. 2007, Liu, Guan et al. 2013). By interacting with anti-apoptotic factors Bcl-xl
and Bcl-2, p53 induces mitochondrial outer membrane permeabilization (MOMP) and apoptosis
(Chipuk, Kuwana et al. 2004, Leu, Dumont et al. 2004). Although these mechanisms are
synonymous with those found in somatic cells, induction of a p53-dependent apoptosis in
damaged hESCs is accelerated as compared to their differentiated counterparts. Interestingly,
two mechanisms have been identified to prime hESCs for rapid apoptotic induction. In the first
mechanism, hESCs maintain pre-activated proapoptotic protein Bax protein within the Golgi,
which upon damage exposure undergoes rapid p53 dependent translocation to the mitochondria
to initiate MOMP (Dumitru, Gama et al. 2012). Alternatively, hESCs can exhibit high mitochondrial
priming, wherein they express higher levels of proapoptotic protein PUMA but lower levels of
antiapoptotic protein Bcl-2 compared to their differentiated counterparts. This lowers the apoptotic
threshold required to elicit a damage induced p53 mitochondrial program (Liu, Guan et al. 2013).
Furthermore, both these hESC apoptotic priming mechanisms are rapidly lost in response to
differentiation.
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In addition to favoring elimination of damaged cells, hESCs express higher levels of DNA
repair factors and repair various DNA lesions more efficiently compared to somatic cells
(Maynard, Swistowska et al. 2008, Momcilovic, Knobloch et al. 2010). hESCs favor high fidelity
homologous recombination (HR) repair rather than error prone non-homologous end joining
(NHEJ) repair of DSBs (Adams, Golding et al. 2010, Nagaria, Robert et al. 2013). Inhibition of
DSB damage sensing kinases, ATM and DNA dependent protein kinase (DNA-PKcs), increases
sensitivity of hESCs to the topoisomerase I inhibitor, camptothecin (Garcia, Videla Richardson et
al. 2014). Interestingly, hESCs do not activate G1/S checkpoint in response to irradiation damage.
Instead exposure to gamma irradiation induced rapid cell death and is accompanied by activation
of ATM and its downstream targets Chk2 and p53 (Momcilovic, Choi et al. 2009). DSBs undergo
Rad51-mediated HHR resulting in sister chromatid exchanges (SCE) and cells elicit a temporary
G2 arrest, before resuming cell cycle progression (Momcilovic, Knobloch et al. 2010). Conversely,
ultra-violet radiation-C range (UVC) light exposure triggers Chk1/Chk2-mediated degradation of
CDC25A (cell division cycle 25 homolog A), prevents cyclin dependent kinase 2 (CDK2) activation
and induction of a G1 arrest (Barta, Vinarsky et al. 2010). In sharp contrast to the presence of
some observable checkpoint activation in response to other genotoxic stresses, hESCs treated
with agents that block the replication fork progression fail to activate the Chk1 mediated intra Sphase checkpoint. Instead, hESCs undergo rapid apoptosis upon exposure to replication stress
inducers like excess thymidine, which disrupts nucleotide pools, or cisplatin which creates interand intra-strand DNA crosslinks (Desmarais, Hoffmann et al. 2012).

V. REPLICATION STRESS RESPONSE

Replicative DNA polymerases frequently encounter obstacles that block fork progression
as they undertake the daunting task of accurately replicating a 6 billion base pair genome. These
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hindrances to fork progression can result from DNA damage exposure, DNA crosslinks,
secondary DNA structure formation, insufficient nucleotide pools and run-ins with the transcription
machinery (Zeman and Cimprich 2014). Encountering these lesions on the lagging strand might
not have lasting consequences for fork progression due to the continual synthesis and priming of
new Okazaki fragments. Conversely, fork stalling on the leading strand can slow fork progression
and in extreme cases lead to uncoupling of the helicase from DNA polymerase (Cortez 2015).
The resulting ssDNA-dsDNA junctions at stressed forks serve as a hub for the recruitment and
interaction of multiple factors essential to the activation of an ATR-Chk1 replication stress
response.
Replication stress signaling is initiated by the binding of ssDNA binding protein, RPA, to
ssDNA formed at stalled forks (Fig. 1-4). ATR in association with its obligate partner ATRIP is
recruited to sites of RPA-coated ssDNA (Cortez, Guntuku et al. 2001, Zou and Elledge 2003).
Independently, clamp loader Rad17 loads PCNA- like heterotrimeric ring complex Rad9-Rad1Hus1 (9-1-1 complex) at ssDNA-dsDNA junctions at stalled forks (Bermudez, Lindsey-Boltz et al.
2003, Majka, Binz et al. 2006). ATR-activator TopBP1 is recruited to these sites though an
interaction with a constitutively phosphorylated site on Rad9 (Ser387) that is essential for TopBP1
binding (Delacroix, Wagner et al. 2007). TopBP1 contains an essential and conserved ATRactivation domain (AAD) and overexpression of this domain alone can induce ATR activation in
absence of DNA damage (Kumagai, Lee et al. 2006, Mordes, Glick et al. 2008). Once activated,
ATR then phosphorylates downstream targets Rad17 (Ser 635) and RPA (Ser 33) (Bao, Tibbetts
et al. 2001, Vassin, Anantha et al. 2009). These phosphorylation sites create docking sites for
Claspin that mediates ATR dependent Chk1 activation (Wang, Zou et al. 2006). Together ATR
and Chk1 kinases can phosphorylate various target proteins to orchestrate a response that
includes regulation of origin firing, stabilization of stalled replication forks, induction of cell cycle
arrest to prevent entry into mitosis and facilitating fork restart after removal of the fork stalling
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Fig 1-4. Activation of ATR-Chk1 signaling at stalled replication forks.
ATR in association with ATRIP are recruited to sites of RPA coated single stranded DNA stretches
formed at stalled replication forks. Rad17 loaded PCNA- like heterotrimeric ring complex Rad9Rad1-Hus1 (9-1-1 complex) at 5’ primer junctions can interact ATR-activator, TOPBP1. Activated
ATR activates the downstream checkpoint kinase Chk1 in a Claspin dependent manner.
Together, ATR and Chk1 kinase phosphorylate target proteins to induce a replication stress
response that includes but is not restricted to delaying and coordinating origin firing, induction of
cell cycle arrest, and stabilization of stalled fork structures (Adapted with permission from
(Cimprich and Cortez 2008)).
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agent or lesion (Zeman and Cimprich 2014). Herein, the mechanisms of some of these signaling
responses are highlighted.

Cell cycle arrest
The ATR-Chk1 signaling also orchestrates a G2/M cell cycle arrest following DNA
damage. The ATR activating ssDNA-dsDNA junctions/structures can result from DSB resection
or those formed at stalled forks due to polymerase and helicase uncoupling. ATR-activated Chk1
kinase can directly phosphorylate the protein phosphatase, CDC25A and target it for degradation.
This prevents cdc25A from removing inhibitory phosphorylations on CDK1/2 of the cyclin-cdk
complex, preventing cell cycle progression and induction of cell cycle arrest.

Regulation of origin firing
In eukaryotes, DNA replication is initiated at multiple sites called origins of replication to
ensure efficient and timely completion of DNA replication in S phase. In every cell cycle, origins
must be licensed during late mitosis and G1 (Blow, Ge et al. 2011). This ATP-dependent process
involves the assembly of a pre-replicative complex which consists of the origin recognition
complex (ORC), CDC6 (cell division cycle 6), CDT1 (chromatin licensing and DNA replication
factor 1) and two molecules of the heterohexameric replicative helicase MCM2-7
(minichromosome maintenance complex) (Gillespie, Li et al. 2001, Remus, Beuron et al. 2009,
Gambus, Khoudoli et al. 2011). The ORC-CDC6 complex recognizes origin DNA and recruits
CDT1. MCM2-7 then interacts with CDT1 at origins and loads onto DNA (Tsuyama, Tada et al.
2005). S-phase CDKs (cyclin-dependent kinase) also restrict origin licensing to G1 by preventing
further loading of MCM2-7 complexes. The firing of replication origins is initiated in S-phase by
the phosphorylation of pre-ORCs by two S-phase kinases, DBF4 dependent Cdc7 kinase (DDK)
and cyclin-dependent kinase (CDK) (Kang, Warner et al. 2014, Fragkos, Ganier et al. 2015).
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CDC45 (cell division cycle 45) and the GINS complex can then associate with and activate the
MCM2-7 helicase (Ilves, Petojevic et al. 2010, Blow, Ge et al. 2011). DNA-unwinds at these fired
origins and DNA replication is initiated.
DNA replication is initiated at origins distributed all over the genome to ensure the timely
completion of our extensive genome. DNA replication is spatiotemporally regulated wherein
origins within specific regions fire during specific stages of S-phase. This spatiotemporal
regulation can be visualized as the onset of distinct DNA replication patterns that correspond to
how far along cells are within S phase (Fig. 1-5) (Chakalova, Debrand et al. 2005). ATR and Chk1
are key regulators of origin firing both in an unperturbed and perturbed S phase (Cortez 2015,
Saldivar, Cortez et al. 2017). They inhibit excess or unscheduled origin firing and coordinate origin
firing under conditions that induce fork stalling. This ensures the efficient distribution and supply
of nucleotides and replication factors needed during DNA replication. Accordingly, deregulated
origin firing in the absence of Chk1 kinase activity decreases inter-origin distance even in the
absence of replication stress. This is accompanied by the premature activation of late S-phase
origin in early S phase, increased damage and replication stress accumulation and decreased
cell survival (Maya-Mendoza, Petermann et al. 2007, Cortez 2015, Saldivar, Cortez et al. 2017).
These effects are alleviated upon knockdown of replication initiation factor CDC45 suggesting
that increased origin firing in the absence of Chk1 regulation causes accumulation of lethal double
strand breaks (Rodriguez, Gagou et al. 2008, Gagou, Zuazua-Villar et al. 2010). Concurrently,
replication stress induced ATR and Chk1 activation prevents global origin firing by blocking
CDC45 loading.
Interestingly, the number of origins licensed for replication is 3 to 20-fold higher than that
required for completion of DNA replication in an unperturbed S phase (Alver, Chadha et al. 2014).
In the absence of fork stalling, reduction in origin licensing by knockdown of proteins of the MCM27 complex does not affect DNA replication rates. However, when fork stalling occurs, otherwise
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Fig 1-5. Spatiotemporal regulation of DNA replication.
Incorporation of nucleoside analogue upon pulse labelling marks active origin clusters. Images
show DNA replication patterns typically observed with progression through S phase a. In early S
phase, active replication foci distributed throughout the nucleus replicate euchromatin. b. In mid
S phase, DNA around the nuclear periphery and nucleolar regions is replicated. c. In late S phase,
large foci of active DNA replication clusters correspond to replication of facultative and constitutive
heterochromatin. (Reproduced with permission from (Chakalova, Debrand et al. 2005))
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dormant origins close to stalled forks can fire to compensate for stalled forks, ensuring completion
of DNA replication. Therefore, while reduction in MCM2-7 levels have no effect on normal
replication rates, these cells exhibit delayed S phase progression and decreased cell survival
when exposed to replication stress inducers (Woodward, Gohler et al. 2006, Blow, Ge et al. 2011).
ATR is crucial to coordinating the completion of DNA replication from these otherwise dormant
origins under conditions of replication stress. Although the exact mechanism of this remains
elusive, ATR exerts a paradoxical coordination of origin firing. Upon exposure to replication stress,
ATR prevents activation of DNA replication within inactive or late-S phase firing origins achieving
a global effect in suppressing origin firing. Paradoxically, ATR-Chk1 promotes firing of dormant
origins adjacent to stalled replication forks within active DNA replication clusters (Ge and Blow
2010). This inhibition of global origin firing prevents the accumulation of stalled forks while
facilitating redirection of crucial replication factors to stalled forks within actively replicating regions
to enable completion of DNA replication from dormant origins (Fig. 1-6). These mechanisms
function together to protect fork integrity.
Consequentially, inhibition of ATR signaling causes unscheduled and deregulated origin
firing. The effects of replication stress are exacerbated under these circumstances, leading to the
titration out of DNA replication factors that are crucial for replication and fork protection resulting
in extensive DNA damage accumulation and loss of viability. Furthermore, even under conditions
of unscheduled origin firing, fork protection mechanisms fail much after the inhibition of ATR
signaling (Toledo, Altmeyer et al. 2013). This has recently been attributed to the titration out of
ssDNA binding protein RPA that is essential for protecting stalled forks. Although RPA pools are
sufficient to protect ssDNA resulting from fork stalling, the increase in ssDNA that accompanies
unscheduled origin firing amid replication stress, leads to a rapid exhaustion of available RPA
pools. Indeed, increasing or decreasing RPA pools correlates with the extent of protection offered
to accumulating ssDNA regions, decelerating or accelerating the impending fork collapse that
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Fig 1-6. Regulation of origin firing by ATR-Chk1 replication stress response.
(A) During unperturbed S phase (left), a few origins fire within DNA replication clusters activated
in early S phase. With progression through S phase, origins of replication are activated within late
S-phase DNA replication clusters. However, in the presence of replication stress (right) replication
forks within the DNA replication clusters active in early S-phase stall. Dormant origins in the
vicinity of stalled forks are activated to promote completion of DNA-replication in early S phase
replication clusters. Concurrently, the ATR-Chk1 replication stress checkpoint inhibits origin firing
26

within inactive/late S phase replication clusters. (B) In the presence of replication stress firing of
dormant origins rescue DNA replication between stalled forks. In the absence of dormant origin
firing replication cannot be completed between stalled forks, which results in DNA damage
accumulation and induction of apoptosis. (Reproduced with permission from (Ge and Blow 2010))
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accompanies unscheduled origin firing amid replication stress respectively. Also, these effects
are alleviated upon inhibition of origin firing. These results suggest that replication stress induced
ATR directed control on origin firing is crucial yet indirect mechanism for preventing fork collapse
(Toledo, Altmeyer et al. 2013, Cortez 2015, Saldivar, Cortez et al. 2017).

Regulation of fork remodeling
Upon encountering lesions that stall replication forks, forks can regress or reverse giving
rise to what are commonly referred to as chicken foot structures. The formation of these structures
reinstates ssDNA regions that form at stalled forks into dsDNA limiting ssDNA accumulation
(Cortez 2015). These structures are also permissive to template switching facilitating replication
of DNA that was otherwise impermissible due to the presence of the fork stalling lesions (Cortez
2015, Saldivar, Cortez et al. 2017). Although these mechanisms can permit fork protection, ATR
ensures tight regulation of the enzymes involved (Couch, Bansbach et al. 2013). The DNA
translocase, SMARCAL1, is one such downstream target of ATR. Upon RPA-dependent
recruitment to stalled forks, SMARCAL1 catalyzes fork regression (Yusufzai and Kadonaga 2008,
Bansbach, Betous et al. 2009, Ciccia, Bredemeyer et al. 2009). ATR-dependent phosphorylation
of SMARCAL1 at Ser 625 is essential to regulating its fork remodeling activity. However,
deregulated fork processing by SMARCAL1 in the absence of ATR activity leads to aberrant fork
structures that are substrates of SLX4-dependent structure nucleases (Couch, Bansbach et al.
2013). This leads to rapid fork collapse, DNA damage accumulation and loss of viability.
Furthermore, these effects are alleviated upon the overexpression of SMARCAL1 S625D, a
phosphomimetic mutant of ATR regulation (Fig. 1-7). This work emphases the importance of ATR
regulation in remodeling and stabilization of stalled forks.
Additionally, the regulated origin firing, and fork remodeling mechanisms might function
concurrently to prevent replication fork collapse. In the absence of ATR regulation, continued
28

Fig 1-7. The replication stress checkpoint regulates fork regression and remodeling.
The DNA translocase SMARCAL1 catalyzes the regression of stalled replication forks resulting in
the formation of a chicken foot structure. In checkpoint proficient cells, ATR regulates fork reversal
and is essential for maintenance of fork integrity. In checkpoint-deficient cells however, stalled
forks undergo uncontrolled remodeling. This results in the formation of structures that are
susceptible to cleavage by SLX4-dependent structure nucleases and fork collapse. (Reproduced
with permission from (Cortez 2015)).
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origin firing would yield increased number of stalled forks that undergo deregulated remodeling,
increasing their susceptibility to endonucleases and causing widespread fork collapse.
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CHAPTER 2

COMING INTO FOCUS: DISCOVERY OF A NOVEL MMR-DEPENDENT DAMAGE
RESPONSE IN HUMAN PLURIPOTENT STEM CELLS
(D.G. is responsible for data shown in Fig. 2- 4B, 4C, 5, 6, 7, 8 and 9B)

Genomic integrity dictates vitality and normal physiological function. Accumulation of
mutations and genomic aberrations could have deleterious consequences for development,
tissue homeostasis, disease progression such as tumorigenesis and even death. As noted earlier
a functional MMR pathway is crucial for genomic stability. MMR directed mismatch removal
increases replication fidelity by three orders of magnitude (Kunkel and Erie 2005). Consequently,
loss of functional MMR leads to an increase in mutation rate which promotes tumorigenesis. The
inheritance of mutations in MMR genes causes a colorectal cancer predisposition syndrome,
Lynch syndrome. Also, MMR function is lost in 10-40% of spontaneously arising colorectal and
other cancers (Lynch, Snyder et al. 2015).

I. MMR-DEPENDENT DNA DAMAGE RESPONSE: LESSONS LEARNED FROM STUDIES IN-VITRO AND
CANCER CELL MODELS

The MMR pathway is essential for invoking a cell cycle arrest and apoptotic response to
certain DNA damaging agents (Duckett, Drummond et al. 1996, Li, Pearlman et al. 2016). Loss
of MMR confers a 100-fold decease in sensitivity to chemotherapeutic SN1 DNA alkylating agents
(Karran 2001). In this regard, understanding the MMR mechanism could guide strategies for the
prevention and treatment of cancer. As outlined earlier, this MMR-dependent sensitivity to these
drugs stems from the generation of mutagenic

Me

G lesions that preferentially mispair with

thymidine during DNA replication (Murray 1987, Kaina, Ziouta et al. 1997). The events following
the recognition of these MeG/T mismatches however have remained largely controversial (Duckett,
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Drummond et al. 1996). Results from test-tube based biochemistry experiments and responses
of transformed cells to

Me

G/T lesion formation have failed to address if and how MMR directed

repair is executed at eukaryotic cellular replication forks. This is further complicated by the
temporal disconnect between the MMR-dependent recognition of

Me

G/T mismatches that occurs

in the first S-phase after exposure to SN1 type alkylating agents, and the requirement that cells
must traverse through two S phases to invoke a permanent G2 arrest and eventual cell death
(Stojic, Mojas et al. 2004, Mastrocola and Heinen 2010). Yet, two independent, but not mutually
exclusive models have emerged from these studies (Fig. 2-1).
A futile cycle model suggests the MMR directs excision of daughter strand DNA across
from the MeG lesion (Kaina, Ziouta et al. 1997, Stojic, Mojas et al. 2004, Mojas, Lopes et al. 2007,
Noonan, Shah et al. 2012). Persistence of

Me

G on the template strand redirects

Me

G/T mismatch

resynthesis, initiating iterative cycles of MMR directed repair. Unable to faithfully replicate across
Me

G lesions, cells accumulate ssDNA gaps after the first cell cycle (Mojas, Lopes et al. 2007). In

the subsequent S phase, replication forks collapse at these gaps creating DSBs and the induction
of a permanent G2 arrest (Stojic, Mojas et al. 2004, Mojas, Lopes et al. 2007). A second, direct
signaling model, suggests that, upon

Me

G/T recognition MMR proteins forms a docking site for

recruitment and activation of proteins important for signaling a cell cycle arrest (Li, Pearlman et
al. 2016). Particularly, MMR proteins are proposed to form a direct interaction platform for ATR
and it’s activator TOPBP1 bypassing the need for the assembly of an ATR-activation module that
forms at ssDNA-dsDNA junctions, a prerequisite for canonical ATR-Chk1 activation (Liu, Fang et
al. 2010). This model however falls short on explaining the temporal disconnect between the
MMR-dependent activation of these cell cycle regulators in the first S phase and onset of a G 2
arrest in the subsequent cell cycle.
As evidenced by these models, mechanistic details of the MMR-directed activity following
Me

G/T lesion recognition remain poorly understood. It is unclear if and how MMR- dependent
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Fig 2-1. Futile cycle and direct signaling models for MMR-dependent cytotoxic response
to MeG lesion formation.
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recognition of MeG/T lesions affects cellular replication forks. In-vitro studies fail to recapitulate the
complexities of how MMR activity might coordinate with the replication machinery. In turn
evidence in support of the futile cycle model indicate that repair activity does not impact on fork
progression or result in fork reversal, a structure commonly formed at and likely important for
protection of stalled forks (Mojas, Lopes et al. 2007). In addition, the direct signaling model poses
that

Me

G/T bound MMR can directly activate cell cycle checkpoint proteins (Li, Pearlman et al.

2016). Considering this, MMR directed futile repair and/or signaling has been speculated to be
executed behind and uncoupled from the ongoing replication fork machinery.

II. IDENTIFICATION OF A NOVEL MMR-DEPENDENT DNA DAMAGE RESPONSE IN HUMAN PLURIPOTENT
STEM CELLS

Transformed cells continually accumulate genetic mutations in culture. Furthermore, to
protect cells against stresses associated with oncogenic transformation, these cells may have an
increased dependence, activation or expression of various of DNA damage response genes.
Specifically, as discussed before, ATR-Chk1 signaling is crucial for protection of forks and cells
experiencing replication stress. In fact, an increase in replication stress is thought to accompany
oncogenic transformation (Zeman and Cimprich 2014). These cells therefore have increased
dependence on ATR-Chk1 signaling for survival. Indeed, inhibition of ATR activity in cells
experiencing oncogene induced replication stress results in rapid DNA damage accumulation and
loss of cell viability (Ruzankina, Schoppy et al. 2009, Gilad, Nabet et al. 2010, Murga, Campaner
et al. 2011, Lopez-Contreras, Gutierrez-Martinez et al. 2012, Schoppy, Ragland et al. 2012).
Given these altered DNA damage responses, the MMR-dependent DNA damage response
observed in transformed cell models could have arisen from carrier mutations and/or altered DNA
damage responses that accompany transformation. We therefore sought to understand the MMRdependent DNA damage response in a non-transformed cell model, human pluripotent stem cells
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(hPSCs). Furthermore, we could harness the pluripotency of this system and differentiate these
cells into human intestinal and colonic organoids. Since loss of MMR promotes tumorigenesis in
the colon it provides for an opportunity to develop a model system to understand how MMR loss
could promote tumorigenesis.
To characterize the MMR-dependent DNA damage response in hPSCs, cell cycle profiles
of human embryonic stem cell line (CT-2), human induced pluripotent line (YK26) and it’s parental
human dermal fibroblasts (HDFa) treated with MNNG for 48 h were examined. Two cancer lines,
HeLa (MMR proficient) and Hec59 (MMR deficient), were similarly treated as positive and
negative controls of the MMR-dependent DNA damage response, respectively. As expected,
MNNG treatment caused increased accumulation of MMR proficient Hela cells in G2/M phase, an
effect which was completely abrogated in MMR deficient Hec59 cells (Fig. 2-2A). These results
were consistent with our previous work, indicating that MNNG treatment induces a MMRdependent G2/M arrest in cancer cell models. Interestingly, cell cycle profiles of both hPSCs lines,
YK26 and CT-2, exposed to alkylation damage displayed large sub-G1 peaks, indicative of
apoptotic induction (Fig. 2-2A). Furthermore, the knockdown of levels of MMR proteins, MSH2
and MLH1, in YK26 iPSCs alleviated sensitivity to alkylation damage as seen by the absence of
this sub-G1 peak upon MNNG treatment (Fig. 2-2B, 2C). These results suggested that hPSCs
elicit MMR-dependent hypersensitivity to MNNG (Lin, Gupta et al. 2014).
iPSCs have a characteristic 16 h cell cycle owing to a shortened G1 phase as opposed to
the 24 h cell cycle duration of most cancer cell lines (Becker, Ghule et al. 2006). Therefore, cells
could have traversed through two S-phases during the 48 h of MNNG exposure before inducing
apoptosis. To assess the timing of this apoptotic response nocodazole synchronized YK26 cells
were treated with MNNG in G1 phase and their cell cycle progression was monitored. Cell cycle
profiles indicated that mock treated cells are predominantly in the first S phase 8 h post
nocodazole release (Fig. 2-3). Exposure to alkylation damage however resulted in a large fraction
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of cells with sub-G1 DNA content at this early time point. Furthermore, knockdown of MMR
proteins completely abrogated this response to alkylation damage (Fig. 2-3). Strikingly, these
results indicated that MMR-dependent hypersensitivity to alkylation damage involves the
induction of an apoptotic response within the first S-phase of damage exposure (Lin, Gupta et al.
2014).

EXPOSURE TO ALKYLATION DAMAGE DOES NOT INDUCE ACTIVATION OF DNA DAMAGE CHECKPOINT
KINASES IN HUMAN PLURIPOTENT STEM CELLS

The novel MMR-dependent damage response of hPCSs contradicted the well-established
and delayed G2 arrest observed in cancer cells in the second cell cycle after damage exposure.
It suggested that MMR-dependent recognition of MeG/T mismatches in the first S-phase leads to
apoptotic induction in hPSCs. These results supported a direct signaling model, wherein MMRdirected

Me

G/T lesion recognition activates DNA damage signaling kinases and checkpoint

proteins initiating early apoptotic induction (Li, Pearlman et al. 2016). To test this, iPSCs and the
HeLa cancer cell line were examined for activation of DNA damage checkpoint kinases, Chk1
and Chk2, 24 h after exposure to MNNG for 24 h. Activation of Chk1 and Chk2 was assessed
by induction of their phosphorylation at Ser-345 and Thr-68 respectively (Stojic, Mojas et al.
2004, Mastrocola and Heinen 2010, Noonan, Shah et al. 2012). Surprisingly, although damage
exposure induced phosphorylation and activation of Chk1 and Chk2 in HeLa cells, no such
activation was observed in damaged iPSCs (Fig. 2-4A). Consistently, two other hESC lines, H1
and CT-2, showed no observable Chk1 or Chk2 activation following damage exposure (Fig. 24B). However, dephosphorylation of these sites late in apoptosis could account for the lack of
observable Chk1 and Chk2 activation at later time points. Therefore, Chk1 and Chk2 activation
was assessed at various time points soon after exposure of nocodazole-synchronized hPSCs
to alkylation damage. Even at these early time points, no induction of Chk1 or Chk2
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Fig 2-2. Alkylation damage induces a MMR-dependent apoptotic response in hPSC
(A) Representative cell cycle profiles of HeLa, Hec59, CT-2, YK26 and HDFa cells lines treated
with 2 μM MNNG for 48 h. Arrows point to cells with sub-G1 DNA content indicative of apoptosis.
(B) Immunoblot of mismatch repair proteins MSH2, MSH6, MLH1 and PMS2 confirming
knockdown of MSH2 and MLH1 in YK26 iPSCs. (C) Representative cell cycle profiles of control,
MSH2 knockdown (MSH2 KD) and MLH1 knockdown (MLH1 KD) YK26 cells treated with 2 μM
MNNG for 48 h. Adapted from (Lin, Gupta et al. 2014)
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Fig 2-3. Alkylation damage induces a MMR-dependent apoptotic response in hPSC directly
out of the first S-phase
Representative cell cycle profiles of control, MSH2 knockdown (KD), or MLH1 knockdown YK26
cells harvested at indicated times after release from mitotic synchronization and exposed to 2 μM
MNNG in G1. Arrows point to cells with sub-G1 DNA content indicative of apoptosis. Adapted from
(Lin, Gupta et al. 2014)
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phosphorylation was observed in damaged iPSCs as compared their mock treated iPSCs (Fig. 24C). However, γH2AX, a marker of replication stress and DSBs, was strongly induced at time
points corresponding to early apoptotic induction (Fig. 2-4C). These results indicated that MMRdependent recognition of

Me

G/T mismatches in the first S-phase leads to apoptotic induction

without the activation of checkpoint kinases (Lin, Gupta et al. 2014).

DNA DAMAGE SENSING KINASES INDUCE MMR-DEPENDENT P53 STABILIZATION AND ACTIVATION IN
HUMAN PLURIPOTENT STEM CELLS EXPOSED TO ALKYLATION DAMAGE

We assessed the role of the tumor suppressor protein, p53, in apoptotic induction in
damaged iPSCs. Although p53 undergoes rapid turnover, its phosphorylation by DNA-damage
sensing kinases like ATR and ATM in response to various genotoxic stresses leads to p53
stabilization in hPSCs (Banin, Moyal et al. 1998, Tibbetts, Brumbaugh et al. 1999, Grandela,
Pera et al. 2007). Subsequently, p53 activates a transcriptional and/or mitochondrial apoptotic
program (Liu, Guan et al. 2013). We therefore, examined stabilization and phosphorylation of
p53 at Ser15 in iPSCs in response to alkylation damage. As expected, alkylation damage
induced rapid p53 phosphorylation and stabilization in iPSCs which was greatly reduced upon
MSH2 knockdown (Fig. 2-5A). We next examined which DNA-damage sensing kinases
activated p53 in damaged hPSCs. To this end, activation of ATR and ATM was assessed in
YK26, H1 and Hela cells 24 h after damage exposure. MNNG treatment induced activation of
both ATR and ATM in all three cell lines, as seen by phosphorylation of Ser 1981 and Ser 428,
respectively (Fig. 2-5B, 5C) (Bakkenist and Kastan 2003, Liu, Shiotani et al. 2011). Furthermore,
addition of small molecule inhibitors to ATR and ATM kinase activities resulted in a partial
reduction in levels of p53 phosphorylation and stabilization in response to alkylation damage
(Fig. 2-5D, 5E). These results suggested that ATR and ATM damage sensing kinases are
activated upon exposure to alkylation damage. Together they activate p53 in a MMR-dependent
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Fig. 2-4. Alkylation damage induces DNA damage marker γH2AX in hPSCs but not the
activation of checkpoint kinases, Chk1 and Chk2.
(A) Immunoblot of P-Chk1 (Ser 345), Chk1, P-Chk2 (Thr 48), Chk2 in YK26 and HeLa cells
harvested 24 h after treatment with 2 μM MNNG for 24 h. Actin used as a loading control. (B)
Immunoblot of P-Chk1 (Ser 345), Chk1, P-Chk2 (Thr 48), Chk2 in H1 and CT-2 hESCs harvested
24 h after treatment with 2 μM MNNG for 24 h. Actin used as a loading control. (C) Nocodazole
released YK26 treated with MNNG were harvest at indicated time points for western blot analysis.
Immunoblot of P-Chk1 (Ser 345), Chk1, P-Chk2 (Thr 48), Chk2 and γH2AX with Actin used as a
loading control. Adapted from (Lin, Gupta et al. 2014)
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Fig. 2-5. ATR and ATM kinases can induce MMR-dependent p53 stabilization and activation
in human pluripotent stem cells exposed to alkylation damage.
(A) Immunoblot of P-p53 (Ser 15) and p53 in control and MSH2 knockdown (MSH2 KD) YK26
cells after treatment with 2 μM MNNG for 24 h. Actin used as a loading control. (B) Immunoblot
of P-ATR (Ser 1981), ATR, P-ATM (Thr 428), ATM in YK26, H1 and HeLa cells after treatment
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with 2 μM MNNG for 24 h. Actin used as a loading control (Experiment performed by Dipika
Gupta). (C) Quantitation of western blots to determine mean fold-change in activation of ATR and
ATM in YK26 cells upon MNNG treatment Western blots were. (D) Immunoblot of P-p53 (Ser 15)
and p53 in H1 cells treated with 2 μM MNNG, an ATR kinase inhibitor (VE-821) and an ATM
kinase inhibitor (KU5593) for 24 h. (E) Quantitation of western blots to determine mean foldchange in activation and stabilization of p53 upon MNNG treatment in the presence and absence
of inhibitors to ATR and ATM kinase activities. Adapted from (Lin, Gupta et al. 2014).
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manner which likely drives apoptotic induction in damaged hPSCs (Lin, Gupta et al. 2014).

I. PREMISE: WHY THE MMR-DEPENDENT DNA DAMAGE RESPONSE IN HUMAN PLURIPOTENT STEM
CELLS INDUCES APOPTOSIS IN THE FIRST-S PHASE AFTER DAMAGE EXPOSURE?

Our work in hPSCs identified a novel MMR-dependent DNA damage response. Although
hPSCs have adapted their DNA damage responses to eliminate cells exposed to genomic insults,
the hyper accelerated MMR-dependent DNA damage response was unforeseen. This apoptotic
induction in the first S-phase sharply contrasted with the delayed G2 arrest previously
characterized in cancer cells (Stojic, Mojas et al. 2004, Mastrocola and Heinen 2010, Lin, Gupta
et al. 2014). While these results befitted the direct signaling model, we found that MMR does not
activate checkpoint kinases in hPSCs exposed to alkylation damage exposure. Instead DNA
damage sensing kinases, ATR and ATM, activate and stabilize p53 promoting apoptotic induction.
Herein, the direct signaling model fails to reconcile the lack of checkpoint kinase activation and
accelerated cell death observed in damaged hPSCs. We however cannot rule out that MMR
undertakes a novel direct signaling module, leading only to p53 activation and apoptosis. This
novel direct signaling response however fails to explain the rapid accumulation of DNA damage,
as seen by the induction of γH2AX, in MNNG treated hPSCs. Paradoxically, the accumulation of
secondary DNA damage as byproduct of MMR-directed repair reactions at

Me

G/T mispairs

seemed more plausible. Yet, if these repair reactions proceeded independently and behind
ongoing forks as predicted by earlier studies, it remained unclear why it would result in differential
outcomes in two different model systems. Therefore, in this work we examined the effects of MMR
dependent MeG/T lesion recognition on the first S-phase more carefully.
Interestingly, a recent study concluded that hPSCs are extremely sensitive to
perturbations to replication fork progression. hPSCs when treated with increased thymidine, which
disrupts nucleotide pools, or cisplatin which creates inter- and intra-strand DNA crosslinks that
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block the replication fork, fail to activate ATR-Chk1 signaling (Desmarais, Hoffmann et al. 2012).
This signaling in transformed cells is crucial for protection of stalled replication forks, coordination
of DNA replication completion and mitigation of DNA damage accumulation (Couch, Bansbach et
al. 2013, Toledo, Altmeyer et al. 2013, Zeman and Cimprich 2014). Increased replication stress
accompanies oncogene-induced transformation and these cells concurrently rely on upregulated
DNA replication stress responses for survival. Failure to activate ATR-Chk1 under these
conditions has been shown to cause accumulation of DSBs due to fork collapse and cell death
(Ruzankina, Schoppy et al. 2009, Gilad, Nabet et al. 2010, Murga, Campaner et al. 2011, LopezContreras, Gutierrez-Martinez et al. 2012, Schoppy, Ragland et al. 2012, Couch, Bansbach et al.
2013, Toledo, Altmeyer et al. 2013).
We therefore hypothesized that MMR must coordinate with DNA replication forks to
correct

Me

G/T mispairs. However, as

Me

G lesions cannot be faithfully replicated, MMR-directed

futile repair would disrupt progression of forks encountering these lesions. Furthermore, we
predicted that the activation of Chk1 signaling in transformed cells mitigates the ensuing
replication stress, facilitating the completion of replication and entry into the second cell cycle. In
contrast, in hESCs the absence of this Chk1 signaling accelerates both DNA damage
accumulation and sensitivity to alkylation damage.
To establish the efficacy of this hypothesis, we tested some initial predictions of the
outcomes this MMR-directed repair might have in hPSCs, particularly in the absence of a
protective replication stress response.
1. MMR directed recognition of lesions generated by MNNG exposure should lead to increased
accumulation of MMR proteins on damaged chromatin.
2. The unwinding of DNA by helicases uncoupled from replicative DNA polymerase at forks
stalled by MMR-direct repair would lead to ssDNA accumulation ahead of stalled forks.
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3. In the absence of a protective replication stress response, stalled forks would be vulnerable
to collapse and breakage leading to DSB formation.
4. DSB repair pathways might be engaged to counteract DSB formation. Consequentially,
inhibition of these repair pathways should increase sensitivity of hPSCs to alkylation damage.

II. RESULTS
MMR proteins associate with MNNG-damaged chromatin
As stated previously, exposure of hPSCs to the alkylating agent, MNNG, induces rapid
MMR-dependent apoptosis. Replication across

Me

G lesions generates

Me

G/T lesions that are

recognized by MMR proteins (Duckett, Drummond et al. 1996, Mastrocola and Heinen 2010). We
therefore assessed if alkylation damage exposure induced recruitment of MMR proteins to
damaged chromatin. Chromatin extracts isolated from H1 hESCs treated with MNNG for 4 h
showed increased accumulation of the MMR proteins MSH2 and MLH1 onto chromatin in
response to MNNG treatment. This indicated that MMR proteins associate with MNNG-damaged
DNA (Fig. 2-6).

MNNG treated hPSCs accumulate ssDNA gaps
In-vitro studies suggest that MMR proteins initiate lesion processing at MeG/T mismatches
culminating in repetitive cycles of futile repair (Kaina, Ziouta et al. 1997). However, the impact of
these futile repair cycles on replication forks encountering
therefore assessed if MMR mediated repair at
across

Me

G lesions remains unclear. We

Me

G lesions impacted replication forks. If repair

Me

G lesions interrupts replication fork progression, we predicted that ssDNA stretches

would accumulate from the uncoupling of DNA polymerase from the replicative helicase at stalled
forks. To this end, a native BrdU assay was used to assess ssDNA accumulation in YK26 cells
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Fig. 2-6. MNNG treatment increases association of MMR proteins with damaged chromatin.
Immunoblot of chromatin enriched fractions prepared from H1 hESCs treated with 2 µM MNNG
for 4 h using antibodies against MSH2 or MLH1. Histone H3 is included as a loading control.
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exposed to MNNG. YK26 were grown in the presence of the thymidine analog 5-bromo-2′deoxyuridine (BrdU) for 24 h to label all cellular DNA. After treatment with MNNG for 4 h,
immunofluorescence analysis was performed under non-denaturing conditions. Under these
conditions, an antibody to BrdU can only access BrdU epitopes in ssDNA stretches. Thus, the
observed increased nuclear BrdU signals upon MNNG treatment (Fig. 2-7A, 7B) was indicative
of ssDNA accumulation, indicative of replication fork disruption (Raderschall, Golub et al. 1999,
Rubbi and Milner 2001).

Unlike cancer cells, MNNG treatment induces rapid double strand break accumulation in
hPSCs.
Although, the accumulation of ssDNA in MNNG treated iPSCs suggested the presence of
fork disruption, we previously reported that Chk1 is not activated under these conditions (Lin,
Gupta et al. 2014). Under replication stress conditions the activation of an ATR-Chk1 signaling is
essential for protection of stalled forks and viability (Couch, Bansbach et al. 2013, Toledo,
Altmeyer et al. 2013, Zeman and Cimprich 2014). hPSCs fail to activate ATR-Chk1 signaling when
treated with agents that block replication forks and undergo rapid apoptosis (Desmarais,
Hoffmann et al. 2012). Therefore, if cells were experiencing MNNG induced replication stress, we
hypothesized the absence of this signaling would cause breakage and endonucleolytic cleavage
of stalled forks. DNA damage accumulation was assessed in YK26 and H1 cells 4 h after MNNG
treatment by staining for phosphorylation of histone variant H2AX (γH2AX), a DNA damage
marker indicative of replication stress and DSBs (Sharma, Singh et al. 2012). MNNG treatment
increased number of γH2AX foci in both hPSCs with approximately 70% of cells containing >10
γH2AX damage foci (Fig. 2-8A, 8B). Concurrently, exposure to MNNG for just 4 h induced
phosphorylation of RPA at Ser 4/Ser 8 and Thr 21 markers of fork collapse and DSB formation,
in YK26 and H1 hPSCs (Fig. 2-8C) (Sirbu, Couch et al. 2011, Toledo, Altmeyer et al. 2013).
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Fig. 2-7. ssDNA stretches accumulate in hPSCs in response to MNNG treatment
(A) Immunofluorescence imaging of BrdU (green) under non-denaturing conditions from YK26
cells grown in BrdU (10 µM) containing media for 24 hours prior to treatment with 2 µM MNNG
for 4 hours. Nuclei are counterstained with DAPI (blue). Nuclear BrdU signals represent regions
of ssDNA. (B) Images in (A) were quantitated and normalized average nuclear BrdU intensity
from one representative experiment is shown. Error bars represent S.E.M. (n > 100).
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Fig. 2-8. MNNG induces double strand break accumulation in hPSCs is hyper accelerated.
(A): Immunofluorescence imaging of DSB marker γH2AX in YK26 and H1 hPSCs 4 h after
treatment with MNNG. Nuclei are counterstained with DAPI. (B) Quantitation of percentage of
cells in (A) with >10 γH2AX (C) Immunoblot of pRPA (S4/S8), pRPA (T21) and RPA in YK26, H1
and HeLa cells harvest immediately or 20 h after exposure to MNNG for 4 h.
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Furthermore, induction of this DSB marker in Hela cells was observed only 20 h after the initial
4h MNNG exposure (Fig. 2-8C). The latter is consistent with pervious reported MMR-dependent
DSB induction in the second S phase after damage exposure (Stojic, Mojas et al. 2004, Mojas,
Lopes et al. 2007). These results suggested exposure of hPSCs to alkylation damage leads to
accelerated DSBs formation.

MNNG induced DSB formation is accompanied by the activation of a MMR dependent DSB
damage response in hPSCs.
DNA damage sensing kinases, ATM and DNA-PKcs, respond to DSBs formed by various
genotoxic agents and orchestrate a DSB damage response (Chanoux, Yin et al. 2009). Upon
activation, ATM is autophosphorylated at Ser 1981 while DNA-PKcs is phosphorylated at Thr
2609 (Chan, Chen et al. 2002, Douglas, Sapkota et al. 2002, Bakkenist and Kastan 2003, Chen,
Chan et al. 2005, Cui, Yu et al. 2005, Yajima, Lee et al. 2006). These phosphorylation events are
crucial to coordinating access of DSBs to repair factors (Ding, Reddy et al. 2003, Block, Yu et al.
2004, Reddy, Ding et al. 2004, Cui, Yu et al. 2005, So, Davis et al. 2009). As MNNG-induced
γH2AX foci formation and phosphorylation of RPA at Ser 4/Ser8 in hPSCs, we assessed the
activation of these upstream DNA damage sensing kinases. We found that in H1 cells, MNNG
treatment induced phosphorylation of ATM at Ser 1981, albeit it was part of a faster migrating
form of ATM with a corresponding decrease in full length ATM levels (Fig. 2-9A). This cleavage
event of ATM is proposed to facilitate apoptosis, preventing DNA damage signaling ensuing from
the extensive DNA fragmentation that accompanies apoptosis (Smith, d'Adda di Fagagna et al.
1999, Wang, Pabla et al. 2006). We also observed damage induced phosphorylation on DNAPKcs at Thr2609 in H1 cells (Fig. 2-9A). Furthermore, targeted disruption of endogenous MSH2
genes in H1 cells, creating MSH2-/- H1 cells (KO1 and KO2), alleviated the activation of these
damage kinases in response to MNNG (Fig. 2-9A). Also, pretreatment of H1 cells with a small
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Fig. 2-9. MNNG induces a ATM and DNA-PKcs dependent double strand break signaling.
(A) Immunoblot of pATM (Ser 1981), ATM, pDNA-PKcs (Thr 2609) and DNA-PKcs in WT and
MSH2-/- (KO1 and KO2) H1 hESCs after treatment with 2 µM MNNG for 4 h. (B) Immunoblot of
pRPA (S4/S8) and RPA in H1 hESCs treated with 2 µM MNNG for 4 h in the presence of inhibitors
to ATR (VE-821; 10 µM), ATM (KU-5593; 100 µM) or DNA-PKcs (NU-7026; 50 µM). Actin is
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included as loading control. (C): Immunoblot of γH2AX in H1 hESCs treated with 2 µM MNNG for
4 h in the presence of inhibitors to ATR (VE-821; 10µM), ATM (KU-5593; 100 µM) or DNA-PKcs
(NU-7026; 50 µM). Actin is included as loading control.
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Fig. 2-10. ATM and DNA-PKcs orchestrate repair of MNNG induced double strand breaks
in hPSC.
(A) Survival of WT and MSH2-/- (KO1 and KO2) H1 hESCs treated with increasing concentrations
of 2 µM MNNG for 4 h in the presence or absence of inhibitors to ATM (KU-5593; 100 µM) or
DNA-PKcs (NU-7026; 50 µM). Percentage cell survival measured by MTT assay immediately
following treatment. (B) Immunofluorescence imaging of DSB marker γH2AX and DSB repair
factor 53BP1 in YK26 iPSCs 4 h after treatment with 2 µM MNNG. Nuclei are counterstained with
DAPI.
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molecule inhibitor to ATM and DNA-PKcs kinase activity decreased phosphorylation of RPA (Fig.
2-9B), consistent with RPA’s role as a downstream target of these damage kinases. However,
inhibition of no single kinase could sufficiently decrease γH2AX signals in MNNG treated cells
(Fig. 2-9C). This suggests that both ATM and DNA-PKcs might function redundantly to signal
DSB formation. Thus, MNNG induces ATM and DNA-PKcs activate DSB signaling in a MMRdependent manner.
Once activated, ATM and DNA-PKcs can initiate activation and recruitment of downstream
repair factors (Summers, Shen et al. 2011). If they are responsible for promoting repair of MMR
dependent, MNNG-induced DSBs, then inhibition of ATM and DNA-PKcs kinase activity would
exacerbate cell death. To test this, cell survival in hESCs pretreated with small molecule inhibitors
to ATM and DNA-PKcs was determined after MNNG treatment. We observed a further
enhancement of the dose dependent cell death of WT H1 cells to MNNG (Fig. 2-10A). Meanwhile,
ATM and DNA-PKcs kinase inhibitors had little effect on the viability of MNNG treated MSH2-/- H1
cells (KO1 and KO2) (Fig. 2-10A). Conjointly, we observed recruitment of DSB repair factor,
53BP1 to MNNG induced γH2AX foci (Fig. 2-10B). These results suggested that increased
sensitivity of WT hESCs to MNNG treatment following inhibition of ATM and DNA-PKcs implied
attempted repair of MNNG induced DSBs.
The rapid accumulation of secondary damage in the form of ssDNA and DSBs in hPSCs
strongly argued in support of the role of MMR directed processing of

Me

G/T mismatches rather

than formation of a MMR-directed signaling module. More importantly, these outcomes closely
mirrored those observed upon the inhibition of ATR-Chk1 replication stress signaling in
transformed cells experiencing hindrances to fork progression (Couch, Bansbach et al. 2013,
Toledo, Altmeyer et al. 2013, Zeman and Cimprich 2014). Based on these initial findings in
hPSCs, we aimed to ascertain the role of the MMR-directed response to alkylation damage as a
replication stress inducer. To this end, we defined and investigated three endpoints that would be

54

crucial to implicate the MMR-directed response to alkylation damage as a replication stress
inducer
1. MMR-directed repair of MeG/T lesions affects replication fork progression.
2. This activates ATR-Chk1 signaling, facilitating delayed yet coordinated completion of DNA
replication.
3. Inhibition of this signaling amidst MMR-directed replication stress induction accelerates DNA
damage accumulation and sensitivity to alkylation damage.
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CHAPTER 3

ATR-CHK1 ACTIVATION MITIGATES REPLICATION STRESS CAUSED BY MISMATCH
REPAIR DEPENDENT PROCESSING OF DNA DAMAGE
Gupta D., Lin B., Cowan A. and Heinen C. D.
Proc Natl Acad Sci U S A. 2018 February 13; 115 (7): 1523-1528

I. ABSTRACT
The mismatch repair pathway (MMR) is essential for removing DNA polymerase errors
thereby maintaining genomic stability. Loss of MMR function increases mutation frequency and
is associated with tumorigenesis. However, how MMR is executed at active DNA replication forks
is unclear. This has important implications for understanding how MMR repairs O6methylguanine/thymidine (MeG/T) mismatches created upon exposure to DNA alkylating agents.
If

Me

G/T lesion recognition by MMR initiates mismatch excision, the reinsertion of a mismatched

thymidine during resynthesis could initiate futile repair cycles. One consequence of futile repair
cycles might be a disruption of overall DNA replication in the affected cell. Herein, we show that
in MMR-proficient HeLa cancer cells, treatment with a DNA alkylating agent slows S-phase
progression, yet cells still progress into the next cell cycle. In the first S-phase following treatment
they activate ataxia telangiectasia and Rad3-related (ATR)-Checkpoint Kinase 1 (Chk1) signaling,
which limits DNA damage, while inhibition of ATR kinase activity accelerates DNA damage
accumulation and sensitivity to the DNA alkylating agent. We also observed that exposure of
human embryonic stem cells to alkylation damage severely compromised DNA replication in a
MMR-dependent manner. These cells fail to activate the ATR-Chk1 signaling axis, which may
limit their ability to handle replication stress. Accordingly, they accumulate double strand breaks
and undergo immediate apoptosis. Our findings implicate the MMR-directed response to
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alkylation damage as a replication stress inducer, suggesting that repeated MMR processing of
mismatches may occur that can disrupt S-phase progression.

II. SIGNIFICANCE:
MMR mediated mismatch correction has largely been recapitulated in the test tube using
mismatch containing DNA substrates. However, a long-standing question remains: how does
MMR respond to

Me

G/T mismatches caused by alkylation damage and does this affect cellular

replication forks. We demonstrate that MMR-mediated processing of

Me

G/T mismatches creates

replication stress, perhaps due to iterative futile repair cycles that affects DNA replication.
Activation of an ensuing ATR-Chk1 mediated replication stress response becomes important for
mitigating DNA damage accumulation and prolonging cell survival. This study provides evidence
that MMR processing may disturb replication forks encountering alkylation damage, which has
important implications for sensitivity to DNA alkylating agents and for the MMR mechanism.

III. INTRODUCTION
The DNA mismatch repair (MMR) pathway repairs mismatches made by the DNA
polymerase, and thus is essential for genomic stability (Modrich 2006). Germline mutations in
MMR genes cause the colorectal cancer predisposition syndrome Lynch syndrome, while 10-40%
of spontaneous colorectal and other cancers also lose MMR function (Lynch, Snyder et al. 2015).
In addition to repairing mismatches, MMR also plays a role in the cellular response to certain
forms of DNA damage (Li, Pearlman et al. 2016). For example, treatment of MMR-proficient cells
with SN1 DNA alkylating agents leads to decreased growth and increased cell death compared to
MMR-deficient cells (Li, Pearlman et al. 2016). How MMR contributes to this response remains
unresolved. SN1 alkylating agents create O6-methylguanine (MeG) lesions, which get mispaired
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with thymidine in S-phase. MMR proteins respond to

Me

G/T mismatches immediately, however,

these cells arrest in the G2-phase of the subsequent cell cycle (Li, Pearlman et al. 2016). Two
models have been proposed to explain these results. One model suggests that recognition of
Me

G/T by the MMR proteins triggers excision of the thymidine-containing strand (Li, Pearlman et

al. 2016). However, persistence of the

Me

G on the template strand leads to

Me

G/T resynthesis,

initiating iterative futile repair cycles (York and Modrich 2006). How these futile cycles are
resolved such that the cells continue into a second cell cycle is not clear. Persistent single
stranded gaps remain after MMR activity that are proposed to become double strand breaks
(DSB) in the next S-phase, causing the G2 arrest (Mojas, Lopes et al. 2007). A second model
suggests that the MMR proteins recognize MeG/T and directly recruit proteins involved in signaling
cell cycle arrest such as Ataxia telangiectasia and Rad3-related (ATR), Ataxia telangiectasia
mutated (ATM), and the checkpoint kinases Chk1 and Chk2 (Li, Pearlman et al. 2016). As the
MMR proteins respond to

Me

G/T in the first S-phase, it is unclear why cell cycle arrest does not

occur until the second cell cycle after

Me

G/T formation (Mastrocola and Heinen 2010). Improved

understanding of the cellular response in the first S-phase following MMR recognition of

Me

G/T

lesions may help resolve these questions.
Interestingly, we recently reported that human pluripotent stem cells (hPSCs) underwent
extensive apoptosis within the first S-phase after alkylation damage (Lin, Gupta et al. 2014). This
immediate response appeared to conflict with the futile cycle model leading us to consider
whether direct signaling was occurring. However, we noted that hPSCs failed to activate Chk1 or
Chk2, which are key regulators of the MMR-dependent damage response in human cancer cell
lines. An earlier study suggested that hPSCs may lack a replication stress response and, as a
result, are extremely sensitive to replication fork perturbations (Desmarais, Hoffmann et al. 2012).
We therefore hypothesized that MMR processing of

Me

G/T lesions might be impeding DNA

replication progression resulting in replication stress that would be detrimental to hPSCs. If true,
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then MMR processing of

Me

G/T lesions might also induce a replication stress checkpoint in

transformed cell models capable of evoking such a response. In this study, we used human
embryonic stem cells (hESCs) and HeLa cervical cancer cells to explore the effect of MMR
processing of

Me

G/T lesions on DNA replication. We find that alkylation damage disrupts DNA

replication and produces hallmarks of replication stress in hESCs, while in transformed cells an
S-phase checkpoint is activated which prevents replication fork collapse and prolongs survival.

IV. MATERIALS AND METHODS
Cell Culture.
hESCs (H1) (obtained from the WiCell Research Institute) were cultured under feeder free
conditions on growth factor reduced Matrigel (Corning®, 356231) coated tissue culture plates in
hESC media (Peprotech, PeproGrow hESC, BM-hESC-500) and passaged by microdissection
every 4-6 days. For experiments, hESCs were passaged using StemPro® Accutase® Cell
Dissociation Reagent (Gibco™, A11105-01) (37˚C, 5-7 min) and equal cell numbers were seeded
on Matrigel coated plates in media containing ROCK inhibitor (Selleck Chemicals, S1049, 10 µM).
Next day, media was replaced with fresh media without ROCK inhibitor. Cells treatments were
performed 3-4 days after passaging. HeLa cells were grown in Dulbecco's Modified Eagle
Medium (DMEM, Invitrogen) containing 10% fetal bovine serum (FBS, Gibco).
MSH2 knockout hESCs were derived using Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPR)/Cas9 gene targeting. A guide RNA targeting the first exon of
MSH2 (GCCGAAGGAGACGCTGCAGT), designed using the online resource crispr.mit.edu, was
cloned into PX330 (Addgene plasmid #42230). A targeting vector containing MSH2 homology
arms PCR amplified from H1 genomic DNA was cloned into vector pLCA.66/2272 (Addgene
plasmid #22733) which contains a loxed cassette acceptor with two tandem heteromeric lox sites
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flanking PGK-puΔtk and EM7-neoR selection cassettes. Although the acceptor cassette was not
utilized in this study, it was used to disrupt Exon 1 of MSH2. The acceptor cassette was subcloned
into a PGK-DTA backbone to provide a negative selection marker (Addgene plasmid #13440).
10 μg of guide RNA and 40 μg of targeting vector were electroporated into H1 hESCs using the
Bio-Rad Genepulser xcell. Cells were plated on DR4 mouse embryonic fibroblasts and after 3
days underwent puromycin (1 μg/mL) selection. Isolated individual surviving colonies were
genotyped by long-range PCR and targeting was confirmed by Sanger sequencing. Sequencing
indicated that both alleles were targeted by Cas9 and the acceptor cassette was introduced within
one allele while the second allele contained insertions and/or deletions that disrupted the reading
frame due to repair by non-homologous end joining.
To generate the MSH2 knockout HeLa cells using (CRISPR)/Cas9 gene the abovementioned guide RNA sequence was cloned into the vector Px459V2.0 (Addgene plasmid #
62988). HeLa cells were transfected with 4 ug of the vector DNA expressing the guide RNA, the
Cas9 cDNA and a puromycin resistance three days after seeding at a density of approximately
70% using Lipofectamine® 2000 Reagent (Invitrogen™,11668019) as per manufactures
instructions. The DNA-lipid complexes were incubated with cells for 6 h after which 1 ml of DMEM
containing 10% FBS, Gibco was added. Next day, cells were transferred to a 10 cm dish and
underwent selection in media containing 1 μg/mL puromycin. Hotshot PCR was performed on
each of the surviving clones (Fwd primer – AGTAGCTAAAGTCACCAGCGTGC and Rev primer
– CATGTACTTGATCACCCCCTGG) and positive clones were identified using a restriction
enzyme screen to determine formation of insertions or deletions at the Cas9 cleavage site. Clones
identified with a positive PCR screen were further screened by Western blot to check for loss of
MSH2 protein expression.
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Chemicals.
N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) (National Cancer Institute Chemical
Carcinogen Reference Standard Repository; CAS: 70-25-7) and O6-Benzylguanine (O6BG;
Sigma; B2292) were dissolved in DMSO and stored at −20°C. Inhibitors to ATR (ATRi) (VE-821),
ATM (ATMi) (KU-5593) and DNA-dependent protein kinase (DNA-Pkcsi) (NU-7026), and small
molecule inhibitor, pifithrin-μ (PFT-μ), purchased from Selleck Chemicals were dissolved in
DMSO and stored at −80°C. These were used at the following concentrations: MNNG: 2 μM,
except in case of MTT assay; O6BG: 25 μM; ATR (VE-821): 10 µM; ATM (KU-5593): 100 µM;
DNA-PK (NU-7026): 50 µM. MNNG treatments involved a 2 h pretreatment and continual
maintenance in O6BG containing media until point of harvest.

Cell

Synchronization,

Cell

Cycle

Analysis

and

3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide (MTT) Assay.
hESCs pretreated with O6BG for 2 h were treated with MNNG for 4 h. Cells were washed
with phosphate buffered saline (PBS) and fresh medium containing O6BG was added. 20 h later
hESCs were harvested for cell cycle analysis. For cell synchronization at G2/M, HeLa cells were
grown in 300 ng/mL nocodazole for 16 h, detached by mechanical shake-off, washed three times
with PBS and re-plated in fresh medium without nocodazole. After 5 h, 25 μM O6BG was added.
After 2 h, cells were treated with 2 μM MNNG and/or ATRi and harvested at different time points
for cell cycle analysis. hESCs and HeLa cells harvested using StemPro® Accutase® and TrypsinEDTA (Gibco) respectively. The cells were washed with PBS and fixed overnight with chilled 70%
ethanol at -20˚C. Fixed cells were washed with PBS and incubated with propidium iodide (20
μg/mL) and RNase A (200 μg/mL) for 30 min at 37°C. After filtration, cell suspensions were
analyzed using a LSRII flow cytometer (BD Biosciences).
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For studies in hESCs, cells were pretreated with O6BG and incubated with increasing
concentrations of MNNG (0.1, 0.2, 0.5, 1 and 2 μM) and corresponding inhibitor in the presence
of O6BG for 4 h. Cell viability was assessed 20 h later following continued incubation in media
containing the corresponding inhibitors. For studies in HeLa cells, cell survival was assessed at
72 h in cells treated with 2 μM MNNG and/or ATRi in the presence of O6BG for 16 h. Cell viability
was determined using Vybrant® MTT Cell Proliferation Assay Kit (V-13154) as per manufactures
instructions.

Total Cell Extracts and Western Blotting.
Total cell extracts were prepared as described in (15). Briefly, harvested cells were lysed
in ice-cold RIPA buffer containing protease inhibitors for 45 min at 4˚C and centrifuged at 16,000
g for 10 min. Supernatants were collected as total cell extracts. Equal protein concentrations of
cell extracts were separated by denaturing SDS-PAGE, transferred onto a PVDF membrane and
Western blot analysis was performed. Antibodies included: Cell signaling: ATR (#2790), p-ATR
(#2853), p53 (#9282), p-p53-Ser 15 (#9284), p-Chk-Ser 345 (#2341), Chk1 (#2345), pChk2-Thr
68 (#2661), Chk2 (#2662) ; Bethyl: MLH1 (550838), MSH6 (A300-023A), PMS2 (556415), RPAS4/S8 (A300-245A), RPA-S33 (A300-246A) p-Chk1-Ser 317 (A304-673A); Sigma-Aldrich: Actin
(A5060); Calbiochem: RPA (NA19L), MSH2 (NA27); EMD Millipore: γ-H2AX (05-636).

Immunofluorescence and Image Analysis.
hESCs were plated on Matrigel-coated Thermanox™ Cell Culture Cover Slips (Nunc™,
174985). To detect DNA synthesis, cells were treated with or without MNNG in the presence of
5-ethynyl-2′-deoxyuridine (EdU) (10 µM). After 4 h, EdU incorporated into DNA was detected
using the Click-iT® Plus EdU Alexa Fluor® 647 Imaging Kit (Molecular Probes, C10640) and
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further processed for immunofluorescence analysis. To assess 53BP1 and Rad51 foci formation
in hESCs, cells were treated with MNNG for 4 h and processed for immunofluorescence analysis.
To assess cleaved-caspase-3, hESCs were treated with MNNG for 4 h and fixed immediately, or
20 h later.
For detection of ssDNA formation, cells were grown in 5-bromo-2′-deoxyuridine (BrdU) (10
µM) containing medium for 16 h and then in BrdU free media for 2 h. Subsequently, they were
treated with O6BG for 2 h, MNNG for 2 h and then fixed 6 h later using chilled methanol for 10
min at -20°C. Cells were then processed for immunofluorescence analysis as described below.
To assess 53BP1 foci formation in HeLa cells, cells were treated with MNNG and/or ATRi
for 14 h and fixed for immunofluorescence analysis. For cleaved-caspase-3 staining HeLa cells
were treated with MNNG and/or ATRi for 16 h, washed three times with PBS and maintained in
fresh medium containing O6BG. Cells were processed for immunofluorescence analysis after 72
h from start of MNNG exposure. To examine replication origin patterns, HeLa cells were
synchronized in G2/M and harvested as mentioned above. Cells were seeded on glass coverslips.
After 5 h cells were treated with O6BG for 2 h and then treated with MNNG. 15 min prior to harvest,
cells were grown in EdU-containing medium to label active origins of replication, followed by
fixation and processing as described below.
Following MNNG treatment, cells were fixed with 4% paraformaldehyde (10 min),
permeabilized with 1% Triton X-100 (10 min) and blocked with 3% goat serum in PBS for 1-2 h at
room temperature (RT). Cells were incubated with primary antibodies (diluted in 3% goat serum
in PBS) and then with Alexa Fluor 488 or Alexa Fluor 568 secondary antibodies (Molecular
Probes) for 1 h each at RT. Antibodies included: γ-H2AX (EMD Millipore; 05-636), BrdU (Santa
Cruz Biotechnology; sc-32323), Rad51 (EMD Millipore; PC130), 53BP1 (Novus Biologicals:
NB100-304) cyclin A (Santa Cruz Biotechnology; sc-271645), cleaved-caspase-3 (BD
Biosciences; 559565). Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) or
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Hoechst-33342 (Life Technologies; 3570), mounted and images were captured using a Zeiss LSM
780 confocal microscope equipped with a Zeiss Plan-apochromat 63X/1.4 NA oil immersion
objective or a Nikon Eclipse Inverted Fluorescent microscope. Image analysis was performed
using MetaMorph.

V. RESULTS

MMR Triggers Rapid Apoptosis in hESCs in Response to MeG Lesions.
We previously reported that hPSCs treated with the DNA alkylating agent N-methyl-N’nitro-N-nitrosoguanidine (MNNG) undergo rapid apoptosis within the first cell cycle (Lin, Gupta et
al. 2014). To confirm the MMR-dependence of this response, we used Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR)/Cas9-mediated gene targeting to disrupt both
alleles of the endogenous MMR gene MSH2 in H1 hESCs. The knockout cells lost MSH2 protein
expression and displayed a decrease in its obligate partner MSH6 (Marra, Iaccarino et al. 1998)
(Fig. 3-1A). MMR-proficient wild-type (WT) hESCs treated for 20 h with MNNG displayed a large
fraction of cells with sub-G1 DNA content in cell cycle profiles as well as increased cleavedcaspase-3 staining, both indicative of apoptotic induction (Fig. 3-1B, C). In contrast, this response
was largely absent in two independent MSH2 knockout clones (KO1, KO2) (Fig. 3-1B, C). To
assess if this result was in response to

Me

G lesions, MNNG sensitivity was examined in the

presence or absence of O6-Benzylguanine (O6BG), a pseudo-substrate-based inhibitor of
methylguanine methyltransferase (MGMT), which normally removes

Me

G lesions from DNA

(Dolan, Roy et al. 1998). In the presence of O6BG, MNNG induced a dose- dependent decrease
in cell survival of WT hESCs while viability of KO1 cells was only modestly affected (Fig. 3-1D).
In the absence of MGMT inhibition, however, sensitivity to MNNG was partially alleviated only in
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Fig.3-1. Recognition of MNNG induced

Me

G lesions by MMR proteins triggers a rapid

apoptotic response in hESCs.
(A) Immunoblot of mismatch repair proteins MSH2, MSH6 and MLH1 confirming knock-out of both
endogenous MSH2 alleles in two independent MSH2 KO clones, KO1 and KO2, created by
CRISPR/Cas9 gene targeting. Actin is included as a loading control. (B) Representative cell cycle
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profiles as measured by flow cytometry at 24 h of WT, KO1 and KO2 hESCs treated with 2 μM
MNNG for first 4 h. Encircled are cells with sub-G1 DNA content indicative of apoptosis. (C)
Immunostaining and confocal imaging for cleaved-caspase-3 of WT, KO1 and KO2 hESCs fixed
immediately (0 h) or 20 h after treatment with 2 μM MNNG for 4 h. Nuclei are counterstained with
DAPI. Scale bars: 20 μm. (D) Percentage cell survival after 24 h of WT and KO1 hESCs treated
with increasing concentrations of MNNG for the first 4 h and in the presence or absence of O6BG
using the MTT assay. All experiments were performed in triplicate.
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WT hESCs. These results indicate that MMR dependent recognition of

Me

G lesions in hESCs

induces apoptosis in the first cell cycle.

MMR Processing of

Me

G/T Lesions Affects DNA Replication Leading to DNA Damage

Accumulation.
To determine how

Me

G lesions lead to MMR-specific cytotoxicity in hESCs we assessed

the impact of MMR activity on replication forks. We predicted that repair across MeG lesions might
interrupt replication fork progression, uncoupling the DNA polymerase from the replicative
helicase resulting in ssDNA stretches (Byun, Pacek et al. 2005). To test this, the thymidine analog
5-bromo-2′-deoxyuridine (BrdU) was added to hESCs for 16 h to label all cellular DNA prior to
MNNG treatment for 2 h and harvesting 6 h later. Immunofluorescence analysis under nondenaturing conditions detects BrdU epitopes accessible only in ssDNA stretches (Rubbi and
Milner 2001). MNNG exposure led to increased nuclear BrdU signals in WT hESCs indicative of
ssDNA accumulation (Fig. 3-2A, 2B). These signals were significantly attenuated in MSH2 KO
hESCs (Fig. 3-2A, 2B). Both control and MNNG-treated cells showed cytoplasmic BrdU signals
previously reported to arise from ssDNA stretches in mitochondrial DNA (Schlegel, Jodelka et al.
2006). As ssDNA is vulnerable to endonucleolytic cleavage into DSBs, we stained for the DNA
damage marker, γH2AX which can be indicative of DSBs and replication stress (Sharma, Singh
et al. 2012, Sirbu, Couch et al. 2012). Increased γH2AX foci were observed in hESCs within 4 h
of MNNG treatment (Fig. 3-3A). Concurrently, DSB repair factors Rad51 and 53BP1 involved in
homologous recombination or non-homologous end joining, respectively, accumulated at sites of
MNNG-induced γH2AX foci only in WT hESCs (Fig. 3-4A-4D). If this damage resulted from MMR
processing of MeG/T lesions, we predicted that its appearance would only occur at replication sites
active during MNNG exposure (Altshuler, Hodes et al. 1996). To test this, we treated cells with
MNNG in the presence of a thymidine analog 5-ethynyl-2′-deoxyuridine (EdU) to mark actively

67

replicating regions. We found γH2AX foci were observed only in cells that incorporated EdU
during MNNG exposure mirroring DNA replication patterns (Fig. 3-3B). Notably, although damage
accumulated at sites of DNA replication, MNNG treatment markedly reduced total EdU
incorporation in WT hESCs indicating that overall DNA replication was severely compromised
(Fig. 3-3C, 5A). These responses were MMR dependent, as MNNG-treated KO1 and KO2 cells
accumulated fewer γH2AX foci with less disruption to DNA replication (Fig. 3-3C, 5A and 5B).
γH2AX foci that did form in KO cells may have resulted from infrequent collisions of replication
forks with base excision repair intermediates from other MNNG generated adducts (Ensminger,
Iloff et al. 2014). Overall, these results suggest that MMR processing at MeG adducts compromises
DNA replication and creates replication stress.
Replication stress can activate a protective ATR-Chk1 signaling axis that prevents
replication fork collapse (Zeman and Cimprich 2014). The formation of DSBs in replicating hESCs
treated with MNNG, however, suggested this replication stress response was lacking. We
examined activation of ATR-Chk1 signaling in MNNG-treated hESCs by measuring
phosphorylation of ATR at Ser 428, of the ssDNA binding replication protein A (RPA) at Ser 33
and of Chk1 at Ser 345 (Lopez-Girona, Tanaka et al. 2001, Olson, Nievera et al. 2006, Liu,
Shiotani et al. 2011). None of these sites appeared phosphorylated following 4 h of MNNG
treatment; a timepoint that likely captures events in the first S-phase after treatment and at which
point γH2AX is already observed (Fig. 3-3D, 6A). Instead, we saw phosphorylation of RPA at S4
and S8 residues, markers of fork collapse, in WT hESCs, which are reduced in the KO hESCs
(Fig. 3-6B). The failure to activate this ATR-Chk1 signaling response was also accompanied by
rapid phosphorylation and stabilization of the tumor suppressor protein p53 in WT hESCs (Fig. 33E). Loss of MSH2 alleviated the levels of p53 phosphorylation in response to MNNG (Fig. 3-3E).
To test if p53 activation induced the apoptotic response, we blocked p53 translocation to
mitochondria using a small-molecule inhibitor pifithrin-µ (Strom, Sathe et al. 2006). Pre-treatment
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Fig. 3-2. MMR-directed repair in MNNG treated hESCs causes accumulation of ssDNA
gaps.
(A) WT and KO1 hESCs with BrdU labeled parental DNA treated with 2 μM MNNG for 2 h. ssDNA
gap formation was assessed 6 h later by immunostaining with BrdU antibody under nondenaturing conditions. Nuclei are counterstained with DAPI. Experiments performed in triplicate.
Scale bars: 10 µm. (B) Quantitation of average nuclear BrdU intensity in MNNG treated WT and
KO1 hESCs from one representative experiment (n>190); (*, **) P ˂ 0.0001, Mann-Whitney test.
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Fig. 3-3. Processing of MeG/T lesions by MMR affects DNA replication, DSB formation and
activation of a p53-dependent apoptosis.
(A) Immunostaining for DSB marker γH2AX in WT hESCs treated with 2 μM MNNG for 4 h. Scale
bars: 10 μm. (B) Immunostaining of γH2AX in WT hESCs treated with 2 μM MNNG for 4 h in the
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presence of EdU (10 μM). EdU incorporation detected using click chemistry. (C) Immunostaining
of γH2AX and EdU incorporation in nuclei of WT, KO1 and KO2 hESCs treated with 2 μM MNNG
and EdU for 4 h. Scale bars: 10 μm. (D) Immunoblot of pATR (Ser 428), ATR, pChk1 (Ser 345),
Chk1, pRPA (S33), RPA and γH2AX in WT hESCs treated with 2 μM MNNG for 4 h. Actin used
as a loading control. (E) Immunoblot of MSH2, MLH1, p-p53 (Ser 15) and p53 in WT, KO1 and
KO2 hESCs treated with 2 μM MNNG for 4 h. (F) Percentage cell survival of WT hESCs assessed
using MTT assay in the presence or absence of pifithrin-μ (20 μM) 24 h after treatment with
increasing concentrations of MNNG for first 4 h. All experiments were performed in triplicate.

71

Fig 3-4. Upon MNNG treatment, homologous recombination (HR) and non-homologous end
joining (NHEJ) repair factors are recruited to sites of MMR-induced double strand breaks.
(A) Immunofluorescence and confocal imaging of γH2AX and HR repair factor Rad51 in WT, KO1
and KO2 hESCs 4 h after treatment with 2 µM MNNG. Nuclei are counterstained with DAPI. Scale
bars: 10 µm. (B) Immunofluorescence and confocal imaging of γH2AX and NHEJ repair factor
53BP1 in WT, KO1 and KO2 hESCs 4 h after treatment with 2 µM MNNG. Nuclei are
counterstained with DAPI. Scale bars: 10 µm. (C) Quantitation of percentage of nuclear area
positive for Rad51 signal. Results from one representative experiment as described in (A)
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(n>300); (*, **, ***) P ˂ 0.0001, Mann-Whitney test. (D) Quantitation of percentage of nuclear area
positive for 53BP1 signal. Results from one representative experiment as described in (B)
(n>250); (*, **, ***) P ˂ 0.0001, Mann-Whitney test.
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Fig 3-5. MMR-dependent processing of

Me

G/T lesions in hESCs compromises DNA

replication and promotes accumulation of double strand breaks.
(A) Quantitation of average nuclear EdU from one representative experiment as performed in Fig
2B (n> 150); (*, **, ***) P ˂ 0.0001, Mann-Whitney test. (B) Quantitation of average nuclear γH2AX
intensities in EdU positive cells from one representative experiment as performed in Fig 2B (n>
150); (*, **, ***) P ˂ 0.0001, Mann-Whitney test.

74

with pifithrin-µ reduced cell death even at the highest MNNG concentrations tested (Fig. 3-3F).
To confirm that ATR activation did not play a role in this rapid response, we co-treated WT hESCs
with MNNG and an inhibitor to ATR kinase activity (ATRi) for 4 h. The addition of ATRi had no
effect on the levels of p53 activation or sensitivity to MNNG at this time point, whereas ATM
inhibition did affect p53 activation at this early stage (Fig. 3-7A, 7C). As we previously had
observed ATR activation 24 h after exposure to MNNG (Lin, Gupta et al. 2014), we tested the
effect of ATRi on p53 activation and/or sensitivity at a later time point. Indeed, addition of ATRi
decreased p53 activation in MNNG treated hESCs after 24 h as did inhibitors to ATM and DNAdependent protein kinase (DNA-PK) (Fig. 3-7B). At the later time point, though, ATRi in
combination with MNNG increased cell death compared to MNNG alone (Fig. 3-7C). This later
activation of ATR may be a response to intermediates of DSB repair, which could explain why
ATRi increased sensitivity to MNNG at this time point (Jazayeri, Falck et al. 2006, Myers and
Cortez 2006). Combined, our results suggest that MMR-processing of
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G/T lesions interferes

with DNA replication but fails to activate an ATR-Chk1-mediated replication stress checkpoint in
hESCs. Instead, these cells accumulate DSBs, consistent with replication fork collapse, and
undergo rapid, p53-dependent apoptosis.

DNA Alkylation Damage Leads to ATR-Chk1 Activation in Cancer Cells.
The effect of MNNG-treatment on DNA replication in hESCs strongly suggested that MMR
dependent processing of MeG/T lesions induces replication stress. However, evidence of MNNGinduced replication stress in transformed cell lines has been largely overlooked due to their
continued progression into the second cell cycle (Mastrocola and Heinen 2010, Li, Pearlman et
al. 2016). We suspected that differences in ATR-Chk1 activation could contribute to the differential
responses between these cell types. To this effect, we first assessed if MMR-proficient HeLa
cancer cells activate Chk1 14 h after MNNG treatment, a time point at which the cells would have
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Fig 3-6. MNNG induced replication stress in hESCs triggers fork collapse without
activating ATR kinase in a MMR-dependent manner
(A) Immunoblot of pATR (Ser 428), ATR, MSH2 and MLH1, in WT, KO1 and KO2 hESCs treated
with 2 μM MNNG for 4 h. Actin used as a loading control. (B) Immunoblot of MSH2, MLH1, pRPA
(S4/S8) and RPA in WT, KO1 and KO2 hESCs treated with or without 2 µM MNNG for 4 h. Actin
is included as loading control.
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Fig 3-7. ATR kinase activity does not contribute to early apoptotic induction in MNNG
treated WT hESCs.
(A) Immunoblot of p-p53 (Ser 15) and p53 in WT hESCs treated with or without 2 µM MNNG for
4 h in the presence of inhibitors to ATR (VE-821: 10 µM), ATM (KU-5593; 100 µM) or DNA-PKcs
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(NU-7026; 50 µM). Actin is included as loading control. (B) Immunoblot of p-p53 (Ser 15) and p53
in WT hESCs treated with or without 2 µM MNNG for 4 h and harvested 20 h later in the presence
of inhibitors to ATR (VE-821: 10 µM), ATM (KU-5593; 100 µM) or DNA-PKcs (NU-7026; 50 µM).
Actin is included as loading control. (C) Percentage cell survival of WT hESCs treated with 2 µM
MNNG for 4 h in the presence or absence of inhibitors to ATR (VE-821: 10 µM). Cell survival was
measured by MTT assay immediately or 20 h following treatment as described in schemes for (A,
B). All experiments were performed in triplicate.
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only entered a single S-phase. We found that under these conditions Chk1 was phosphorylated
on Ser 317 and Ser 345; an effect that was abrogated by the addition of ATRi (Fig. 3-8A). We
also tested the MMR-dependence of this response by using CRISPR-Cas9 gene targeting to
disrupt the endogenous MSH2 alleles in HeLa cells and observed no activation of Chk1 upon
MNNG exposure in two independent MSH2 KO clones (Fig. 3-9A). We next investigated if Chk1
activation induced an intra-S-phase replication checkpoint. HeLa cells synchronized in mitosis
were released into the cell cycle, treated with MNNG or vehicle control in G1 phase and allowed
to progress through the cell cycle. Cell cycle profiles of mock-treated cells showed entry and
completion of the first S-phase by 10 h and 18 h post-release, respectively (Fig. 3-8B). MNNG
treatment however, delayed progression through S-phase with a significant cell population still in
S-phase at 18 h (Fig. 3-8B). A salient feature of the intra-S-phase checkpoint is coordinated
completion of DNA replication thereby mitigating DNA damage accumulation (Blow, Ge et al.
2011). Within replication factories, ATR-Chk1 mediates activation of dormant replication origins
adjacent to stalled forks while delaying replication onset within inactive clusters. We therefore
predicted that MNNG treatment would delay replication onset within replication clusters active late
in S-phase. To visualize active replication factories, synchronized HeLa cells were pulse-labeled
with EdU 15 minutes prior to harvest. We observed distinct replication foci patterns that emerge
from spatio-temporal regulation of DNA replication in S-phase (Fig. 3-8C) (Chakalova, Debrand
et al. 2005). In control cells in early S-phase (10 h), active DNA replication clusters were observed
throughout the nucleus. Mid and late S-phase DNA replication patterns were discernable at 14 h
wherein DNA replication was observed at the nuclear periphery and nucleolar regions. DNA
replication was completed by 16 h. In MNNG- treated cells, although early S-phase origin
activation patterns were visible at 10 h, DNA replication continued within these clusters until 16h.
In addition, activation and completion of DNA replication within mid and late S-phase replication
factories was delayed to 16 h and 20 h, respectively. MNNG treatment also appeared to reduce
the percentage of EdU-positive cells suggesting a delayed entry into S-phase. However, careful
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Fig. 3-8. MNNG treatment in HeLa cells induces an ATR-Chk1 dependent replication stress
checkpoint that allows delayed, yet coordinated completion of replication.
(A) Immunoblot of pChk1 (Ser 345), pChk1 (Ser 317) and Chk1 in MMR proficient HeLa cells
treated with 2 μM MNNG and an ATR inhibitor (ATRi) (10 μM) for 14 h. Actin used as a loading
control. Experiments were performed in triplicate. (B) Representative cell cycle profiles of HeLa
cells harvested at indicated times after release from mitotic synchronization and exposed to 2 μM
MNNG in G1 in the presence or absence of ATRi. Percentage of cells in S phase at 18 h
quantitated from the cell cycle profiles are: untreated (14.4%), MNNG (39.3%), ATRi (16.6%) and
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MNNG + ATRi treated (18.4%) (C) HeLa cells treated with 2 μM MNNG as described in B were
pulsed with EdU 15 min prior to harvest. EdU incorporation marking actively replicating DNA
clusters was detected using click chemistry. Experiments were performed in duplicate. Scale bars:
10 μm.
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Fig 3-9. MMR processing of MNNG induced lesions in HeLa cells activates an ATR-Chk1
dependent replication stress checkpoint.
(A) Immunoblot of pChk1 (Ser 345), pChk1 (Ser 317), Chk1, MSH2 and MLH1 in MSH2 WT and
MSH2 KO (KO1 and KO2) HeLa cells treated with 2 μM MNNG for 14 h. Actin used as a loading
control. Experiments were performed in triplicate. (B) Overexposure of 10 h time point images in
Fig 3C to visualize percentage of nuclei positive for EdU incorporation. Arrows point to nuclei that
are truly negative for EdU incorporation in untreated cells harvested at 10h even at high
exposures. Arrowheads point to nuclei that appear negative for EdU incorporation at low exposure
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in MNNG treated cells harvested at 10 h, but are actually positive for EdU at high exposure. Scale
bars: 10 μm. (C) Quantitation of EdU positive cells from one representative experiment as
described in Fig. 3C visualized at high exposure.
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inspection of these cells revealed that the number of Edu-positive cells was only slightly reduced.
Rather, the intensity of EdU staining was low in many cells consistent with delayed replication
progression and not delayed S-phase entry (Fig. 3-9B and 9C). These results suggest that MNNG
treatment induces a replication stress checkpoint in transformed cells that allows delayed, yet
coordinated completion of replication.

ATR-Chk1 Mitigates DNA Damage Accumulation in Response to MeG–Induced Replication
Stress.
In addition to coordinating replication completion, an ATR-Chk1-mediated intra-S-phase
checkpoint is crucial for protecting stalled forks from collapse and preventing apoptosis (Couch,
Bansbach et al. 2013, Toledo, Altmeyer et al. 2013, Zeman and Cimprich 2014). We, therefore,
predicted that inhibiting the ATR kinase in MNNG-treated HeLa cells should cause collapse of
stalled forks, thereby exacerbating DNA damage accumulation and cell death. To this effect, we
assessed if ATR-Chk1 signaling slowed S-phase progression of MNNG-treated HeLa cells. HeLa
cells co-treated with ATRi and MNNG completed their first S-phase by 18 h, a rate comparable to
that of untreated cells (Fig. 3-8B). We next examined whether ATRi led to increased DSBs in the
first cell cycle after MNNG treatment by measuring 53BP1 foci formation at 14 h. Using cyclin A
to identify S and G2 cells, we found that mock treated cells contained 1-5 53BP1 foci when in G1,
consistent with previously reported baseline endogenous DNA damage levels in transformed cells
(Fig. 3-10A and B) (Bekker-Jensen, Lukas et al. 2005, Lukas, Savic et al. 2011). However, 53BP1
foci (> 10 per cell) increased in MNNG-treated G1 nuclei. A G1 specific increase in 53BP1 foci has
previously been attributed to the sequestration of DNA damage carried forward through mitosis
into the subsequent cell cycle (Lukas, Savic et al. 2011). Thus, these observed foci may arise
from unreplicated gaps created by MMR processing of
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G/T lesions during S-phase in cells that

then progressed to the next G1 during the 14 h experiment (Mojas, Lopes et al. 2007).
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Fig. 3-10. ATR-Chk1 signaling in the first S phase is crucial to mitigating DNA damage
accumulation in MNNG treated HeLa cells.
(A) Immunostaining for 53BP1 and cyclin A, a S/G2 phase marker, in HeLa cells treated with 2
μM MNNG in the presence or absence of ATRi (10 μM) for 14 h. Arrows point to cyclin A negative
nuclei with >10 53BP1 foci. Arrowheads point to cyclin A positive nuclei with >10 53BP1 foci. (B)
Quantitation of percentage nuclei in G1 and S/G2 cell cycle phase with >10 53BP1 foci. ((*, **,
****) P ≤ 0.01, (***, *****) P ≤ 0.05, Student’s t-test). (C) Immunoblot of pChk2 (Thr 68), Chk2,
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pRPA (S4/S8) and RPA in HeLa cells treated with 2 μM MNNG in the presence or absence of
ATRi (10 μM) for 14 h. Actin used as a loading control. (D) Immunostaining for cleaved-caspase3 at 72 h in HeLa cells treated with 2 μM MNNG for the first 16 h in the presence or absence of
ATRi (10 μM). Scale bars: 20 μm. (E) Quantitation of percentage of cells positive for cleavedcaspase-3 staining (P ≤ 0.01, Student’s t-test). (F) Cell survival assessed using MTT assay at 72
h in HeLa cells treated with MNNG for the first 16 h in the presence or absence of ATRi (10 μM).
(P ≤ 0.01, Student’s t-test). All experiments were performed in triplicate.
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Consequently, the number of MNNG-induced 53BP1 foci was greatly reduced upon MSH2 loss
(Fig. 3-10B and 11A). In contrast, ATRi addition to MNNG-treated WT cells altered the dynamic
of 53BP1 foci formation, wherein increased numbers of 53BP1 foci accumulated in cyclin A
positive S and G2 nuclei (Fig. 3-10A, 10B and 11A). No such increase in 53BP1 foci in cyclin Apositive S and G2 nuclei was observed in MSH2 KO HeLa cells (Fig. 3-10B and 11A). These
damage foci therefore may be a consequence of replication forks collapsing due to MMR-induced
replication stress (Sirbu, Couch et al. 2012, Couch, Bansbach et al. 2013, Toledo, Altmeyer et al.
2013). Correspondingly, combining MNNG and ATRi in WT cells induced phosphorylation of Chk2
and RPA at S4/S8 within 14 h, indicative of DSB formation and replication fork collapse
respectively within the first cell cycle of MNNG exposure (Sirbu, Couch et al. 2012, Couch,
Bansbach et al. 2013, Toledo, Altmeyer et al. 2013) (Fig. 3-10C). We next determined how
addition of ATRi during the first cell cycle affected viability of MNNG-treated HeLa cells. We found
that while cell survival decreased slightly in MNNG treated WT-HeLa cells 72 h after damage
exposure, addition of ATRi for only the first 16 h of MNNG exposure significantly reduced viability
as seen by increased cleaved-caspase-3 staining, excessive DNA fragmentation and overall
decrease in cell number at 72 h (Fig 3-10D-F). The induction of DSB markers and increased
sensitivity to MNNG in the presence of ATRi were alleviated in both MSH2 KO HeLa clones (Fig.
3-11B-D). Overall, these results indicate that ATR-Chk1 signaling in the first S-phase after MNNG
treatment is crucial for limiting DNA damage accumulation and promoting cell survival in the face
of replication stress caused by MMR-mediated processing of MeG/T lesions.

VI. DISCUSSION
MMR has long been implicated in eliciting cytotoxicity to SN1 DNA alkylating agents (Li,
Pearlman et al. 2016). The steps following
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G/T recognition, however, are not entirely clear,

particularly as MMR-proficient transformed cells undergo G2 arrest only after cells go through two
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S-phases. Both a direct signaling model, in which MMR proteins directly recruit factors involved
in signaling cell cycle arrest to damaged DNA, as well as a futile cycle model, in which iterative
cycles of repair at MeG/T lesions leads to downstream DNA damage that ultimately triggers arrest
have been proposed (Li, Pearlman et al. 2016). In both models, it is unclear if MMR activity
coordinates with the replication fork or whether MMR occurs in a post-replication manner leaving
the passing fork unaffected. If the former, repair events occurring at the fork could lead to fork
disruption and therefore impair DNA replication. As MMR-proficient cancer cells were shown to
complete the first S-phase after treatment with DNA alkylating agents, it appeared that DNA
replication proceeded uninterrupted amidst active MMR (York and Modrich 2006, Mastrocola and
Heinen 2010, Li, Pearlman et al. 2016). However, our recent observation that hESCs undergo
rapid MMR-dependent apoptosis directly in the first S-phase following alkylation damage led us
to re-examine the effects of MMR on the first S-phase more carefully (Lin, Gupta et al. 2014).
Herein, we observed that MeG lesions generated by MNNG decreased hESC viability within just 4
h. This was accompanied by increased ssDNA and DSB formation in cells that underwent DNA
replication. Most strikingly, besides accumulating damage at replication foci, overall DNA
replication was severely impacted in MMR-proficient hESCs. These results provide evidence that
the MMR-mediated response to MeG/T lesions indeed affects DNA replication.
We propose that cancer cells tolerate MMR-mediated disruption to the replication fork via
activation of an ATR-Chk1-intra-S-phase checkpoint that facilitates continued cell cycle
progression into the next cell cycle (Fig. 3-12). While the majority of MNNG treated cells will
ultimately arrest in the next G2 phase, the transient intra-S-phase response likely expands the
opportunity for some cells to escape this fate. A failure to activate ATR-Chk1 under conditions of
replication stress has been shown in transformed cells to cause increased ssDNA accumulation
at stalled forks (Couch, Bansbach et al. 2013, Toledo, Altmeyer et al. 2013, Zeman and Cimprich
2014). Vulnerable to breakage, these paused forks can collapse, leading to accumulation of lethal
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Fig 3-11. DNA damage accumulation upon inhibition of ATR-Chk1 signaling in the first S
phase of MNNG treated HeLa cells is dependent on functional MMR
(A) Immunostaining for 53BP1 and cyclin A, a S/G2 phase marker, in WT and MSH2 KO1 HeLa
cells treated with 2 μM MNNG in the presence or absence of ATRi (10 μM) for 14 h. (B)
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Immunoblot of pChk2 (Thr 68), Chk2, pRPA (S4/S8) and RPA in WT and MSH2 KO (KO1 and
KO2) HeLa cells treated with 2 μM MNNG in the presence or absence of ATRi (10 μM) for 14 h.
Actin used as a loading control. (C) Immunostaining for cleaved-caspase-3 at 72 h in WT and
MSH2 KO (KO1 and KO2) HeLa cells treated with 2 μM MNNG for the first 16 h in the presence
or absence of ATRi (10 μM). Nuclei are counterstained with DAPI. Scale bars: 20 μm. (D)
Quantitation of percentage of cells positive for cleaved-caspase-3 staining (P ≤ 0.01, Student’s ttest).
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DSBs. We found that chemical inhibition of ATR-Chk1 signaling in MNNG-treated HeLa cells
resulted in induction of markers of fork collapse and DSBs within the first cell cycle such as
phosphorylation of RPA and Chk2, respectively, as well as increased S- and G2-phase 53BP1
foci. In addition, ATR inhibition accelerated sensitivity to MNNG. Given the ability of transformed
cells to normally cope with replication stress in this way, it is not surprising that the effect of MMR
processing of

Me

G/T mismatches on global DNA replication has gone largely unnoticed. In

contrast, hESCs appear to lack a protective ATR-Chk1 signaling cascade in response to MNNG
as well as other inducers of replication stress (Desmarais, Hoffmann et al. 2012) and instead
accumulate ssDNA and DSBs and rapidly apoptose. Thus, the effects of MMR processing of
Me

G/T lesions on global DNA replication are more apparent. The inability of these cells to complete

DNA replication may stem from an absence of dormant origin firing in response to active forks
failing to bypass MeG lesions. The apoptotic induction in hESCs is much more rapid compared to
HeLa cells, a discrepancy which may arise from the primed nature of hESCs to undergo apoptosis
at the slightest signs of stress (Liu, Guan et al. 2013).
The MMR-dependent induction of replication stress in response to MeG/T lesions fits nicely
in the context of the futile cycle model. Repetitive repair cycles may inhibit DNA replication
progression resulting in fork stalling and, in the absence of ATR-Chk1 activity, fork collapse.
Alternatively, futile processing at multiple

Me

G/T lesions may utilize extensive amounts of RPA,

known to bind to the ssDNA gaps generated during MMR processing (Genschel and Modrich
2003, Zhang, Yuan et al. 2005). This may require activation of ATR-Chk1 signaling in order to
prevent RPA exhaustion that has effects on fork stability more globally (Toledo, Altmeyer et al.
2013). Support for a direct signaling mechanism is less obvious from our results. Despite the early
cell death in hESCs, we observe a lack of activation after treatment from proteins implicated in
the direct signaling model such as ATR, Chk1 and Chk2 (Li, Pearlman et al. 2016). This reduced
damage signaling would seem counterintuitive to the accelerated cell death observed in these
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Fig. 3-12. Model of the effects of the MMR-directed response to
replication progression.
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Me

G/T lesions on DNA

cells. In HeLa cells treated with MNNG, the cells do not undergo an arrest until the second cell
cycle after treatment. Thus, a temporal disconnect remains between the initiation of MMR activity
in the first cell cycle and cell cycle arrest in the next. However, we cannot rule out the possibility
that the MMR proteins are initiating a direct signaling response in the first S-phase that protects
HeLa cells initially after treatment to prevent replication fork collapse. This scenario would still
require an additional function of the MMR proteins to cause the eventual cell cycle arrest that
occurs in the next G2-phase. What is clear is that ATR-Chk1 signaling is crucial for protecting cells
from the detrimental effects of DNA replication disruption by MMR processing of alkylation
damage. Future studies will be required to investigate how MMR proteins communicate with the
DNA replication machinery to cause this disruption.
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CHAPTER 4

CONCLUSIONS AND FUTURE DIRECTIONS

Replication across MeG lesions results in formation of MeG/T lesions that are recognized by
MMR proteins. But the events ensuing lesion recognition have remained elusive. In transformed
cells, MMR-dependent recognition of

Me

G/T lesions in the first S phase elicits a permanent G2

arrest in the subsequent cell cycle and culminates in cell death (Duckett, Drummond et al. 1996,
Stojic, Mojas et al. 2004, Mastrocola and Heinen 2010, Li, Pearlman et al. 2016). Yet, hPSCs
activate a MMR-dependent apoptotic response within the first S phase itself (Lin, Gupta et al.
2014). We therefore aimed to resolve how MMR-dependent

Me

G/T mismatch recognition could

yield differential responses/outcomes within these two model systems by ascertaining the effects
of lesion recognition on the first S phase.

VI. MMR-DIRECTED RESPONSE TO ALKYLATION DAMAGE AS A REPLICATION STRESS INDUCER

In-vitro studies have described MMR-directed excision of the erroneous strand as a crucial
step for mismatch correction (Kunkel and Erie 2005, Modrich 2006). Yet, how this post replicative
repair is executed at cellular replication forks is unclear. The interaction of MMR proteins with the
DNA polymerase processivity factor, PCNA, could suggest a possible linkage between the fork
and the repair process (Hidaka, Takagi et al. 2005, Mastrocola and Heinen 2010). Amid such a
coordination, rapid and efficient repair of simple DNA mismatches may not yield a discernable
impairment to fork progression. Alternatively, repeated cycles of MMR-directed excision and
Me

G/T mismatch resynthesis could disrupt the fork movement. However, these iterative cycles of

MMR activity caused no observable effects on global DNA replication in transformed cell models
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(Mojas, Lopes et al. 2007). This suggested that MMR’s interaction with PCNA likely facilitated
their localization to the fork to enhance mismatch recognition. Additionally, MMR activity was
inferred to be executed in the wake of the replication fork (Mojas, Lopes et al. 2007). Interestingly,
we observed that futile repair cycles initiated by MMR in hESCs severely affected DNA replication.
In this study we provide evidence for a previously unobserved coordination between MMR activity
and the replication fork. Herein, we define the MMR-directed response to alkylation damage as a
replication stress inducer based on three measured endpoints
1. MMR-directed repair of MeG/T lesions affects completion of DNA replication.
2. Subsequent activation of ATR-Chk1 signaling facilitates delayed yet coordinated
completion of DNA replication.
3. Inhibition of ATR-Chk1 signaling amidst this MMR-directed repair accelerates DNA
damage accumulation and sensitivity to alkylation damage.

When considering the mechanism of MMR-induced replication stress it is important to note
key distinctions compared to that of other known replication stress inducers. Canonical replication
stress inducers like aphidocolin and hydroxyurea inhibit DNA-polymerase activity or cause
nucleotide pool depletion respectively. This causes an acute and rapid inhibition of individual fork
movement. In DNA fiber labelling assays, this culminates in an abrupt disruption of thymidine
analogue incorporation and significantly shorter labeled nascent strand DNA stretches compared
to untreated controls (Merrick, Jackson et al. 2004). The ensuing ATR-Chk1 replication stress
response inhibits replication initiation within inactive and late firing origin clusters (Ge and Blow
2010). Additionally, replication factors are redirected to active DNA replication clusters to
maximize replication completion and minimize ssDNA stretches (Toledo, Altmeyer et al. 2013).
Even under these conditions, perturbations to fork movement are prominent and new origin firing
is prevented until favorable conditions are reestablished.
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Conversely, the subtle effect of MMR activity on fork movement has made studying the
coordination between MMR and replication machinery particularly difficult. As MMR does not
affect DNA-polymerase activity directly or via depletion of nucleotide pools, inhibition on fork
movement is not acute. Rather, DNA fiber labelling assays would likely yield labeled nascent DNA
strands of varying length depending upon when and if the fork encounters a

Me

G lesion. Strand

resynthesis after MMR directed excision would further confound the identification of affected forks.
Secondly, ATR-Chk1 signaling could coordinate usage of replication factors to complete and
minimize the effects on global DNA replication (Fig. 4-1). Replication patterns observed in
synchronized HeLa cells elude to this signaling mediated replication rescue (Fig. 3-8C). Upon first
entering S-phase, synchronized HeLa cells exposed to alkylation damage exhibit a marked
decrease in incorporation of the thymidine analogue EdU (Fig. 3-8C). This would suggest that
MMR-activity affects DNA replication very early in S-phase. However, as ATR-Chk1 signaling is
established the effect on global DNA replication becomes indiscernible at later time points.
Dormant origins proximal to stalled forks likely facilitate the delayed completion of DNA
replication. Thirdly, ATR and Chk1 are key regulators of origin firing even in an unperturbed S
phase (Cortez 2015, Saldivar, Cortez et al. 2017). Inhibition of Chk1 kinase activity causes
deregulated origin firing and decreased inter-origin distance in the absence of replication stress
(Maya-Mendoza, Petermann et al. 2007). Premature activation of late S-phase origin is
accompanied by increased damage and replication stress accumulation (Syljuasen, Sorensen et
al. 2005, Rodriguez, Gagou et al. 2008, Gagou, Zuazua-Villar et al. 2010, Toledo, Altmeyer et al.
2013). These confounding effects of inhibiting ATR-Chk1 signaling in a cancer cell model would
further affect the ability to investigate the coordination between MMR activity and replication
machinery (Fig. 4-2).
Our success in identifying the MMR-directed response to alkylation damage as a
replication stress inducer is largely attributed to the lack of an ATR-Chk1 replication stress
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Fig. 4-1. Proposed model by which the activation of an ATR-Chk1 replication stress
response in transformed cells protects forks stalled by MMR-directed processing of
alkylation damage while facilitating completion of DNA replication.
(A) Iterative cycles of MMR-directed processing at forks encountering MeG lesions on the template
strand disrupts fork progression. (B) MMR-induced fork stalling results in uncoupling of DNA
helicase from the replication machinery resulting in ssDNA stretches. RPA protects ssDNA
generated at stalled forks preventing fork breakage. RPA bound to ssDNA recruits DNA
translocase, SMARCAL1, initiating fork reversal mediated fork protection. Activation of the ATRChk1 replication stress response prevents aberrant fork processing. ATR-Chk1 signaling
promotes dormant origin firing in the proximity of forks stalled by MMR-directed futile cycles of
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repair to facilitate completion of replication of intervening DNA while preventing activation of
inactive/late S phase replication clusters. This minimizes ssDNA stretches, ensures maximum
completion of DNA replication, relieving the need for fork reversal mediated fork protection leaving
only short ssDNA stretches across from MeG lesions. (C) Progression through S phase continues
albeit slowly and ATR-Chk1 mediated fork protection mechanisms ensure that DNA replication
similarly completed within late S phase replication clusters.
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Fig. 4-2. Proposed model for accelerated damage accumulation upon inhibition of ATRChk1 signaling in transformed cells experiencing MMR-induced fork stalling in response
to alkylation damage.
ATR-Chk1 signaling coordinates origin usage to limit the number of forks experiencing MMRmediated futile processing at any given time. Inhibition of ATR-Chk1 signaling results in
deregulated origin firing and premature activation of late S-phase. This would significantly
increase the number of forks experiencing MMR-directed fork stalling simultaneously.
Consequentially, large number of ssDNA stretches accumulate at forks stalled by MMR. As
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ssDNA stretches exceed cellular RPA pools, RPA mediated fork protection mechanisms fail
leading to fork breakage and replication catastrophe. Also, in the absence of ATR-directed
regulation of DNA translocase, SMARCAL1, reversed forks undergo aberrant processing leaving
them susceptible to structure specific endonucleases, resulting in fork breakage and double
strand break formation.
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response in hESCs (Desmarais, Hoffmann et al. 2012). Low levels of ATR-Chk1 activation might
be sufficient to coordinate replication in an unperturbed S phase. But, absence of an ATR-Chk1
replication stress response limits their ability to tolerate fork stalling (Desmarais, Hoffmann et al.
2012). Instead, hPSCs favor elimination when exposed to genomic insults. Consequentially, we
could discern the effects of MMR-activity on fork progression in the absence of ATR-Chk1
signaling but without the DNA damage cross-talk offered by ATR-Chk1 inhibition. Under these
conditions, MMR-activity in response to alkylation damage severely compromises DNA replication
with extensive and rapid damage accumulation (Fig. 4-3). In this work, we propose that the ATRChk1 signaling is crucial to mitigating the effects of MMR-induced replication stress in response
to alkylation damage. We propose the following protection and/or compensatory mechanisms that
might be offered by ATR-Chk1 signaling in response to MMR-induced replication stress
conditions.

Use of dormant origin firing
Slowed progression through S-phase in MNNG-treated HeLa cells is marked by persistent
activation of early S-phase replication clusters and delayed activation of late replicating clusters
(Fig. 3-8C). As discussed earlier, ATR-Chk1 signaling is thought to control origin firing to mitigate
the effects of replication stress. In cancer cell models, this signaling could promote dormant origin
firing in the proximity of forks stalled by MMR-directed futile cycles of repair to facilitate completion
of DNA replication (Fig. 4-1). The contribution of dormant origin firing to replication completion
could be assessed in HeLa cells using adapted DNA fiber labelling assays (Merrick, Jackson et
al. 2004). By labelling nascent DNA consecutively with two different nucleoside analogues,
replication stress induced latent origins usage would yield decreased inter-origin distances.
Alternatively, number of licensed origins could be reduced via a partial knockdown of origin
licensing factor, MCM. As licensed origins far exceed that required during unperturbed DNA
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replication, a decrease in origin licensing has little effect on DNA replication in HeLa cells
(Woodward, Gohler et al. 2006, Alver, Chadha et al. 2014). Conversely, if MMR-proficient HeLa
cells exposed to alkylation damage rely on dormant origins to rescue DNA replication, then
decreased origin licensing would compromise global DNA replication. This could also lead to
accelerated DNA damage accumulation and increased sensitivity to alkylation damage, like that
observed in hESCs. Furthermore, the ability of transformed cells to coopt dormant origin firing to
cope with replication stress would provide further evidence to support why the effects of MMR
processing of MeG/T mismatches on global DNA replication have largely gone unnoticed.
Interestingly, the mechanisms by which ATR-Chk1 signaling regulates origin firing remain
unclear. Some studies suggest that dormant origin firing is independent of replication stress
checkpoint activation. Rather, continued association of pre-replicative complex with chromatin
near stalled forks causes firing of otherwise dormant origins (Blow and Ge 2009). Others indicate
that ATR-targeted MCM phosphorylation near stalled forks allow these origins to evade the
checkpoint-mediated origin suppression (Cortez, Glick et al. 2004, Yoo, Shevchenko et al. 2004).
An understanding of the dynamics and usage of dormant origin firing in hESCs could therefore
provide valuable insights into these complex regulatory mechanisms. DNA fiber labeling assays
mentioned above could help inform dormant origin usage in hESCs in response to MMRprocessing of alkylation damage. The absence of decreased inter-origin distances in hESCs
would affirm the inability to complete DNA replication between stalled forks and explain the
decrease in global DNA replication we reported under these conditions.
But, the inability to replicate intervening DNA could arise from the lack of excess licensed
origins, limited origin firing factors and/or lack of ATR-Chk1 mediated activation of licensed
dormant origins (Fig. 4-3). hESCs might license only as many origins as are required to complete
replication in the absence or presence of low levels of replication stress. Correspondingly,
increased origin licensing in hESCs by overexpression of origin licensing factors like Cdt1 or
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CDC6 should reduce basal replication-stress associated damage accumulation and sensitivity to
alkylation damage. Origin licensing in the absence of their usage in hESCs could be regarded as
an energetically wasteful process. The shortening of origin licensing G1 phase might therefore
allude to an evolutionary mechanism to restrict the ability of hPSCs to tolerate replication stress
(Becker, Ghule et al. 2006). Indeed, lengthening the origin licensing G1 phase in mESCs
decreases basal levels of replication stress (Ahuja, Jodkowska et al. 2016). This study proposed
that longer G1 phases allowed for adequate resolution of DNA damage. However, they did not
assess increased origin licensing under these conditions. Also, decreasing origin licensing in
hESCs promoted differentiation (Matson, Dumitru et al. 2017). As hESCs exposed to genotoxic
stress also undergo differentiation, it could suggest that origin licensing in hESCs is limited and a
decrease in licensing factors increases endogenous stress. Under these conditions, low levels of
stress might prompt differentiation to promote survival and tissue homeostasis while preventing
hPSCs experiencing even low perturbations to fork progression from accumulating DNA damage
that could affect normal tissue functioning. Also, increased expression of origin licensing factors
accompanies transformation (Blow and Gillespie 2008, Zimmerman, Jones et al. 2013).
Therefore, by assessing how levels of chromatin-loaded MCM in hESCs correlate with that found
in cancer cells, increased origin licensing could be indicative of oncogenic transformation.
Conversely, the ability of overexpression of the origin firing factor, CDC45, to reduce both
endogenous and replication-stress associated DNA damage accumulation would suggest that
origin firing and not licensing is limiting in hPSCs. More interestingly, as hESCs do not activate
ATR-Chk1 checkpoint signaling, the ability of these mechanisms to rescue global DNA replication
would indicate that regulation of origin firing in response to fork stalling is independent of
checkpoint control. However, the inability of these mechanisms to counteract the effects of
replication stress associated damage would suggest that ATR-Chk1 signaling is important for
activation of dormant firing. If so, replication stress induced upregulation of ATR-Chk1 signaling
upon oncogenic transformation could directly promote increased origin firing to mitigate
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accumulation of replication stress associated damage. Additionally, it would suggest that
increased origin usage in cancer cells is an ATR-Chk1 induced adaptation to oncogenic
replication stress.

RPA mediated protection of ssDNA stretches
In our work we observed that inhibition of ATR kinase accelerated damage accumulation
and fork collapse in MMR-proficient HeLa cells treated with MNNG. Additionally, the increase in
chromatin loading of RPA in response to alkylation damage in transformed cells expressing a
kinase dead mutant of ATR would suggest an ATR-mediated control on ssDNA accumulation
(Stojic, Mojas et al. 2004). These point to a model wherein ATR-Chk1 signaling limits ssDNA
accumulation and protects forks stalled by MMR activity in response to alkylation damage (Fig.
4-1). Indeed, intra-S phase checkpoint mediated coordinated origin usage has been implicated in
limiting damage accumulation at stalled forks. Particularly, as the helicase uncouples from DNA
polymerase, the continued unwinding of parental DNA generates large ssDNA tracts (Byun,
Pacek et al. 2005). These regions are coated and protected by the ssDNA binding protein, RPA,
until replication is completed by replication initiation from a nearby dormant origin. Concurrently,
checkpoint mediated suppression of late origin firing ensures that number of stalled forks are low
and ssDNA stretches are kept at a minimum, facilitating cell survival (Toledo, Altmeyer et al.
2013). However, in the absence of functional ATR-Chk1 signaling deregulated origin firing leads
to formation of ssDNA that exceed cellular RPA pools. Lack of protection of these ssDNA regions
leaves them prone to breakage causing fork collapse (Toledo, Altmeyer et al. 2013).
As per this model, the intra-S phase checkpoint could limit the number of forks
experiencing MMR-mediated futile processing at any given time thereby maintaining low levels of
ssDNA stretches that are protected by RPA (Fig. 4-1). Thus, MMR-proficient cancer cells
complete DNA replication leaving short unreplicated gaps observed in electron micrographs that
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correspond to the remnants of excision reactions across from
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G lesions (Mojas, Lopes et al.

2007). Conversely, deregulated origin firing upon ATR-Chk1 inhibition in transformed cells would
significantly increase the number of forks experiencing MMR-directed fork stalling simultaneously
(Fig. 4-2). Subsequently, cellular RPA pools capable of fork protection would be exhausted,
leading to fork breakage. To this end, increasing or decreasing cellular RPA pools should delay
or accelerate collapse of forks stalled by MMR-directed futile processing at multiple MeG/T lesions
in cancer cells respectively.
Furthermore, we propose an alternative form of deregulated origin firing in hESCs in
response to MMR-induced replication stress. In this model, MMR-directed futile cycles disrupt
fork progression, uncoupling the helicase from the DNA polymerase creating ssDNA stretches
(Byun, Pacek et al. 2005). However, the inability to complete DNA replication from adjacent
origins would leave these large stretches of ssDNA unresolved (Fig. 4-3) (Blow, Ge et al. 2011).
Additionally, without activation of an intra-S phase checkpoint late origin firing would continue
uninterrupted (Ge and Blow 2010). Under these conditions, the continued accumulation of large
ssDNA stretches would exhaust cellular RPA pools leading to fork collapse. Also, increasing or
decreasing cellular RPA pools should delay or accelerate collapse of forks stalled by MMRdirected futile processing in hESCs respectively.

Fork reversal and processing
Fork reversal is important for protection and stabilization of stalled forks. Yet, electron
micrographs of forks isolated from MMR-proficient transformed cells exposed to alkylation
damage show no evidence of fork reversal (Mojas, Lopes et al. 2007). This suggested that MMR
activity must be executed behind the ongoing fork and has no effect on fork progression. Firing of
dormant origins under these conditions would not be required. MMR activity would be expected
to create ssDNA gaps of similar length in both hPSCs and transformed cells. Additionally, as
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these cell systems express equal amounts of cellular RPA, one would predict that concurrently
the RPA-mediated protection would be similar (Fig. 2-8C). It is therefore hard to comprehend why
the absence of ATR-Chk1 signaling would lead to accelerated damage accumulation and
sensitivity to alkylating agents in both these model systems.
Herein, we suggest that MMR-induced fork stalling does cause fork reversal (Fig 4-1).
However, ATR-Chk1 signaling mediated completion of DNA replication by a converging fork
relieves the need for protection of ssDNA through the formation of a chicken foot structure.
Subsequently, the inability to faithfully replicate across MeG lesions leaves only small ssDNA gaps
at the end of the first S phase (Mojas, Lopes et al. 2007). Additionally, as ATR signaling prevents
aberrant fork processing from generating structures that are susceptible to SLX4-dependent
endonucleases, compromised fork integrity in the absence of ATR signaling would also explain
accelerated damage accumulation and sensitivity to alkylating agents in both these model
systems (Fig. 4-2) (Couch, Bansbach et al. 2013).
Interestingly, mESCs experience increased frequency of fork reversal in response to
higher levels of endogenous replication stress compared to their differentiated counterparts
(Ahuja, Jodkowska et al. 2016). Similar signs of increased endogenous replication stress have
also been reported in hESCs. Thus, in the absence of external stimuli low levels of basal ATR
activation might suffice to regulate SMARCAL1 activity at the limited number of forks experiencing
replication stress, ensuring their appropriate fork processing. Conversely in presence of
replication stress inducers, these low levels of ATR activation might not suffice/fail to regulate
SMARCAL1 directed remodeling at rapidly accumulating stalled forks (Fig. 4-3). As a result,
MMR-induced replication stress would be evidenced by increased fork reversal in hESCs exposed
to alkylation damage. Similarly, such MMR-mediated processing in cancer cells in the absence of
ATR signaling would also lead to increased frequency of fork reversal. Additionally, fork collapse
and increased sensitivity resulting from deregulated processing at these forks would be alleviated
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by knockdown of either the DNA translocase SMARCAL1 involved in fork processing or SLX4,
the structural subunit of structure-specific endonucleases.
Evidence supporting fork reversal mediated protection of forks stalled by MMR could
provide important insights into the mechanism of MMR. In vitro, strand discrimination is always
directed by a nick on one strand that serves as an entry site for MMR-mediated excision by an
exonuclease (Holmes, Clark et al. 1990, Thomas, Roberts et al. 1991). However, the source of
these discontinuities on replicating cellular DNA has remained a long-standing question in the
field. The ends of the Okazaki fragments in the lagging strand and the single 3’ end of the leading
strand would make for the most consistent potential entry sites for MMR-associated exonuclease
loading. At forks encountering
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G lesions, repeated mismatch generation and MMR-directed

excision from these sites could require pausing of replication machinery to allow the repair
process to occur. Even so, excision reactions on the lagging strand may not have lasting
consequences on fork progression as replication could be rescued by the priming of new Okazaki
fragments. On the leading strand however, the effect of futile cycles of repair on the fork may be
much more severe. Interestingly, SMARCAL1 catalyzes reversal of stalled forks with leading
strand gaps created upon uncoupling of the replicative helicase and leading-strand polymerase
(Betous, Couch et al. 2013). Therefore, an alleviation in fork collapse and sensitivity to alkylation
damage caused by a lack of ATR-Chk1 signaling in either transformed cells or hESCs upon
knockdown of SMARCAL1 would provide evidence supporting the role of MMR-mediated
daughter strand excision reactions in compromising progression of the leading strand
polymerase. Furthermore, with the entry site for the 5’-3’ directed exonuclease 1 on the leading
strand still being a point of contention, it would be interesting to see if generation of nicks 5’ to the
G lesions by PMS2’s endonuclease activity changes the dynamic of fork reversal, ssDNA
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accumulation, fork collapse and sensitivity to alkylation damage in the absence of ATR-Chk1
signaling in transformed cells and hESCs. These results would provide more direct insights into
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Fig. 4-3. Proposed model for accelerated damage accumulation in the absence of ATRChk1 replication stress response in hESCs experiencing MMR-induced fork stalling in
response to alkylation damage.
(A) Iterative cycles of MMR-directed processing at forks encountering MeG lesions on the template
strand disrupts fork progression. (B) MMR-induced fork stalling results in uncoupling of DNA
helicase from the replication machinery resulting in ssDNA stretches. RPA protects ssDNA
generated at stalled forks preventing fork breakage. RPA bound to ssDNA recruits DNA
translocase, SMARCAL1, initiating fork reversal mediated fork protection. In the absence of ATRmediated regulation of SMARCAL1, reversed forks undergo aberrant fork processing leaving
them susceptible to structure specific endonucleases, resulting in fork breakage and double
strand break formation. However, in the absence of dormant origin firing in the proximity of forks
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stalled by MMR-directed futile cycles of repair intervening DNA remains unreplicated. (C)
Progression through S phase continues, and DNA replication is initiated within late S phase
replication clusters. As the number of forks experiencing MMR-directed fork stalling increases,
the accumulating levels of ssDNA increase. Once, ssDNA stretches exceed cellular RPA pools,
RPA mediated fork protection mechanisms fail leading to fork breakage and replication
catastrophe cellular RPA pools. Additionally, as aberrant remodeling of stalled forks continues in
the absence of ATR regulation, forks collapse and double strand breaks accumulate.
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how MMR directs excision on the leading strand particularly at forks encountering alkylation
damage.

VII. MMR-INDUCED REPLICATION STRESS: POTENCY TO CHEMOTHERAPEUTIC DNA ALKYLATING
AGENTS

Understanding the protective role of ATR-Chk1 signaling in response to MMR-induced replication
stress conditions has provided important insights into the mechanistic understanding of MMR
activity at the fork. However, this work also has crucial implications from a therapeutic stand point.
Early work in transformed cells by other groups have recurrently noted an upregulation and
increased dependence on ATR-Chk1 signaling. Since, ATR and Chk1 kinases have been deemed
crucial for protecting transformed cells from replication stress accompanying oncogenic
transformation. As a result, inhibition of ATR-Chk1 signaling has made for a viable and actively
sought-after avenue for selectively sensitizing cancer cells either alone or in conjunction with
replication stress inducing chemotherapeutic agents (Zabludoff, Deng et al. 2008, Ma, Janetka et
al. 2011, Toledo, Murga et al. 2011, Foote, Lau et al. 2015). Our work suggests that these
mechanisms could extended to alkylation-based chemotherapeutics in the clinic used to treat
MMR-proficient cancers. Along these lines, in the two transformed cell systems we tested, HeLa
cells and the osteosarcoma cell line U2OS, we observed a MMR-dependent increase in sensitivity
to alkylation damage upon ATR inhibition (Fig. 4-4). As an extension to these studies it would be
interesting to understand if replication stress induced checkpoint activation is a characteristic of
cancer stem cells and/or observed in adult stem cell systems. Therefore, by classifying the MMRdirected response to alkylation damage as a replication stress inducer our work provides crucial
and

exciting

avenues

for

therapeutic

intervention

chemotherapeutic DNA alkylating agents.
110

towards

increasing

sensitivity

to

Fig. 4-4. Inhibition of ATR-Chk1 signaling in the first S phase increases sensitivity of U2OS
cells to alkylation damage.
Immunostaining for cleaved-caspase-3 at 72 h in U2OS cells treated with 2 μM MNNG for the first
16 h in the presence or absence of ATRi (10 μM).
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VIII. MMR-INDUCED REPLICATION STRESS: SELECTION PRESSURES FOR LOSS OF MMR, SURVIVAL AND
TUMORIGENESIS

MMR is critical for the maintenance of genomic stability. Although individuals with Lynch
syndrome are initially heterozygous for a mutant MMR gene, a spontaneous mutation or loss of
heterozygosity event at the wild type allele confers complete loss of MMR function (Lynch, Lynch
et al. 2009). Also, 10-40% of spontaneously arising colorectal and other tumor types lose MMR
function (Heinen 2014). But delineating the physiological factors that drive cells to lose MMR
function early in tumorigenesis poses a significant challenge. Furthermore, as DNA polymerase
errors go uncorrected, the subsequent increased mutation burden accompanying MMR loss is
ascribed to promote tumorigenesis (Loeb 1991, Kat, Thilly et al. 1993, Fishel, Lescoe et al.
1994). Conventionally, loss of MMR has been speculated to promote tumorigenesis via this
indirect mechanism.
Yet, unexpectedly, in our day-to-day culturing we observed that MSH2 knockout hESCs
consistently outgrew MMR proficient hESCs. Upon quantitation, it was noted that within five
days three different MSH2-/- hESCs achieved cell densities that were two to four-fold higher
compared to MMR proficient wildtype hESCs (Fig. 4-5A) (Madden-Hennessey, unpublished
results). Also, MSH2 loss in hESCs significantly reduced the basal number of γH2AX damage
foci, which are proposed to arise from the increased levels of endogenous replication stress
inherent to embryonic stem cells (Fig. 4-5B) (Ahuja, Jodkowska et al. 2016). These results would
indicate that MMR activity somehow induces DNA damage and/or replication stress in cultured
hESCs.
Considering our newly identified role of MMR directed processing as a replication stress
inducer, we would predict that DNA lesions created by normal cellular metabolism and/or
environmental factors engage MMR. Depending on the relative abundance of these lesions,
MMR could elicit replication stress induced cytotoxicity and/or slowed cell cycle progression.
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Fig. 4-5. Loss of MMR activity in hESCs decreases basal damage accumulation and
increases cell growth
(A) WT, KO1, KO2 and KO3 hESCs seeded at equal cell density were assessed for

average viable cell density over five consecutive days using Trypan blue exclusion
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method. (B) Immunostaining for DNA damage marker γH2AX in WT, KO1, KO2 and KO3
hESCs in culture.
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Furthermore, stem cells experiencing such replication stress likely undergo apoptosis in part
due to the intense pressure on these cells to maintain genomic stability and normal physiology.
Thus, environmental stresses that promote formation of lesions responsible for activating MMRdirected replication stress induced cytotoxicity would pose a strong selection pressure for loss
of MMR activity. The subsequent loss of functional MMR would directly result in the acquisition
of a survival advantage over MMR-proficient cells (Fig. 4-6). In this manner, we propose that
loss of functional MMR directly promotes early stages of tumorigenesis wherein the subsequent
accumulation of mutations within tumor suppressor genes and oncogenes would further
exacerbate the growth advantage to promote cancer progression. Also, studies ascertaining the
exact nature and sources of these stresses and lesions would help inform cancer prevention
measures especially in Lynch syndrome patients. Herein, we describe some putative stresses
that might pose strong selection pressures to lose MMR function:

Environmental pressures
The MMR-dependent increase in basal damage accumulation in hESCs would suggest
that lesions capable of engaging MMR are generated either as a byproduct of cellular
metabolism or stresses inherent to culturing hESCs. The outcomes of the ensuing MMR activity
on hESCs however remain unclear. Understanding if MMR loss reduces background cell death
and/or shortens cell cycle duration of hESCs in culture could help ascertain the nature of the
advantage offered by loss of MMR. The resulting survival and/or growth advantage could help
ascertain how cells selected for loss of MMR function promote initial stages of tumorigenesis in
an otherwise MMR-proficient tissue. Determining the nature, sources and MMR-directed
responses to these lesions could therefore provide important insights into lesions and more
importantly, selection pressures, most likely to arise within the physiological environment of
tissues.
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Oxidative stress resulting from cellular metabolism could be one such source of lesions
that is capable of engaging MMR (DeWeese, Shipman et al. 1998, Hanawalt 1998, Barnes and
Lindahl 2004). Particularly, 8-oxoguanine (8-oxoG) lesions created by oxidation of guanine
resides within DNA mispair with adenine during DNA replication (Shibutani, Takeshita et al.
1991). These 8-oxoG/A lesions are recognized by MMR proteins and could elicit MMR directed
repair like that observed in response to
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G/T lesions (Ni, Marsischky et al. 1999, Mazurek,

Berardini et al. 2002). In a similar futile cycle response, resulting MMR activity would be
predicted to induce replication stress, which in hESCs is cytotoxic (Fig. 4-6). Interestingly,
mESCs heterozygous or homologous for MMR loss show decreased sensitivity to low doses of
oxidative damage (DeWeese, Shipman et al. 1998). Furthermore, this is accompanied by
increased accumulation of mutagenic oxidative lesions. On these lines it would be interesting to
understand how MMR responds to low doses of 8-oxoguanine (8-oxoG) lesions. Work in this
direction could help ascertain if environments prolific in oxidative stresses would pose a strong
selection pressure for loss of MMR. On similar lines, our work herein would suggest that
environments rampant with alkylation damage would pose a strong pressure to lose MMR
activity (Fig. 4-6). Diet and metabolic byproducts of colonic bacterial populations are already
known sources of N-nitroso compounds (Povey, Hall et al. 2000). Colonic stem cells resident to
such environments would have an increased propensity to lose MMR function to bypass MMRdependent cytotoxicity. Studies targeting an understanding of these response in hESCs and
subsequently in tissue specific stem cells, like colonic stem cells could help redefine MMR genes
as classical tumor suppressors and guide cancer prevention methods, particularly in relation to
dietary intake.
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Pressures driven by other somatic mutations
Thus far we have largely described MMR-induced futile repair cycles initiated by
preferential mispairing of modified bases during DNA replication as a potent replication stress
inducer. The coordination between MMR-directed repair and fork movement would have the
repeated engagement of MMR-directed processing be disruptive for fork progression. Therefore,
conditions wherein MMR-activity is repeatedly engaged due to frequent base mispairing could
also affect fork progression (Fig 4-6). While these might not cause a potent blockade to fork
progression, the affected fork movement could elicit cytotoxicity especially when the frequency
of introducing DNA replication errors is particularly high. Namely, oncogenic transformation is
associated with high levels of replication stress and exhaustion of nucleotide pools (Bartkova,
Rezaei et al. 2006, Di Micco, Fumagalli et al. 2006, Bester, Roniger et al. 2011, Venkitaraman
2011). In the absence of sufficient nucleotide pools, progression of DNA polymerase is affected.
Additionally, this could increase frequency of nucleotide misincorporations. Consequentially, it
could result in increased canonical MMR activity, which would further impede fork progression.
As misincorporation rate increases, fork progression would be increasingly affected leading to
apoptotic induction in hESCs and tissue-specific stem cells. In this manner, acquisition of
oncogenic mutations could place an increased selection pressure to lose MMR to promote
oncogenic transformation (Fig. 4-6).
Interestingly, sporadic colon cancers with the oncogenic BRAF-V600E mutation frequently
also have loss of MLH1 protein expression resulting from hypermethylation of the MLH1
promoter (Deng, Bell et al. 2004). Additionally, whether loss of MLH1 precedes acquisition of
the oncogenic BRAF mutation has been a major point of contention in the field. Our hypothesis
suggests that acquisition of mutant BRAF in the initial stages of oncogenic transformation could
drive increased replication rates, nucleotide pool depletion and increased nucleotide
misincorporation. The resulting MMR-induced replication stress would however suppress
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Fig. 4-6. MMR-induced replication stress as a selection pressure for loss of MMR function
in the acquisition of a direct survival advantage during early transformation.
Environmental stresses like reactive oxygen species or N-nitoso compounds generate DNA
lesions that are preferentially paired with the wrong nucleotide during DNA replication. Also,
depletion of nucleotide pools caused by increased proliferation during oncogenic transformation
or acquisition of other somatic mutations that affect DNA replication fidelity to introduce DNA
mismatches. Increased MMR-activity at sites of nucleotide misincoporations can affect fork
progression and induce replication stress. These perturbations to fork progression could trigger
apoptosis, placing an increased pressure to lose MMR function. Under these conditions, loss of
MMR function would result in a direct survival advantage and clonal expansion of MMR-/- cells to
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initiate transformation. The increased in mutation load following loss of MMR function would
promote and accelerate cancer progression.
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expansion of this cellular subset creating a strong selection pressure to lose MMR activity
leading to MLH1 promoter hypermethylation and loss of MLH1 protein expression (Kane, Loda
et al. 1997, Veigl, Kasturi et al. 1998, Deng, Bell et al. 2004). Similarly, this activity also would
explain why tumor cells carrying an inactivating mutation in the proofreading domain of DNA
polymerase ε also lose MMR function (Yoshida, Miyashita et al. 2011). Studies in this direction
would ascertain increased MMR activity to be a stringent bottleneck to early oncogenic
transformation and understand the role of different transforming principles in creating strong
selection pressures for MMR loss.

IX. SUMMARY

In conclusion, by ascertaining the effects of MMR-dependent MeG/T mismatch recognition
on the first S phase our work shows that MMR-mediated processing of alkylation damage affects
fork progression. Activation of ATR-Chk1 signaling is required to mitigate ensuing replication
stress, damage accumulation and facilitate completion of DNA replication. Taken together, we
define the MMR-directed response to alkylation damage as a replication stress inducer. This
work changes how we view this post-replicative repair pathway, suggesting a coordination
between MMR activity and the replication fork. Furthermore, understanding MMR activity in the
context of a replication stress inducer has far reaching implications for the mechanism of MMR,
early tumorigenesis, cancer prevention and chemotherapeutics.
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